

Curriculum Vitae



General Information

Name: Tomassetti Sara
Tax ID: TMSRA74T62H199R

Place of Birth: RAVENNA, ITALY
Date of Birth: 22 Dec. 1974
Marital Status: married, one 16 years old son

Office Address:
Interventional Pulmonology Unit
Careggi University Hospital
Largo Brambilla 3
Florence
ITALY

Home Address:
via Bagnolo 48
47011 Castrocaro Terme e Terra del Sole (FC)
ITALY

E-Mail : s.tomassetti@gmail.com
MOBILE: (+39) 347 8247783

Active Licensure

- 1 June 2001, Italian Medical License, Bologna, Italy.
- 4 September 2001, subscription to the National Medical Association (Albo dei Medici Chirurghi, Forli-Cesena, #4241).
- 31 October 2018, Associate Professor of Respiratory Medicine, Italian National Scientific License
- 22 June 2021, Management of Healthcare Administrations, Bologna University, Italy

Inactive Licensure

- Australian Medical Council licensure, between 2014 and 2018

Education and Academic Profile

1. 20/10/2000, Medical Degree, summa cum laude honor. Bologna Medical School, Italy
2. 27/10/2004, Pulmonary Medicine Specialization, Pulmonary Medicine School, Modena, IT
3. 31/10/2018, License for Associate Professorship in Respiratory Medicine, Abilitazione Scientifica Nazionale Ministero Università e Ricerca, Italy
4. 2018-2019 Professorship (annual contract), Master of Interventional Pulmonology, Università Politecnica delle Marche, Ancona, IT
5. **Since March 1st, 2020 Associate Professor , Respiratory Medicine, Florence University**, Department of Experimental and Clinical Medicine, Careggi University Hospital, Florence, Italy.

Postdoctoral Training

1. **03/2003-04/2004, Research Fellowship**, Respiratory and Crit Care Med (Prof. SD Shapiro), **Harvard Medical School**, Brigham and Women's Hospital, Boston, MA, USA
2. 2005-2006, Clinical research fellowship in Pulmonary Medicine, clinical trials on IPF, Interventional Pulmonary Unit (Prof. V Poletti), GB Morgagni Hospital, Forlì, Italy
3. May 2008; Sept 2009; August 2010; August 2011, May 2012, Nov 2013, Aug 201. **Visiting Clinician Program**, Respiratory and Crit Care Med (Prof. JH Ryu), **Mayo Clinic, Rochester USA**
4. August 2018, Visiting Clinician at Respiratory and Crit Care Med (Prof. H Collard and B Ley), **UCSF, CA, USA**.

Appointments at Hospitals

1. 2006- 29/2/2020, **Consultant**, Pulmonary Physician, Pulmonary Medicine Unit, Thoracic Department GB Morgagni Hospital, Forlì, Italy
2. 1/3/2020-currently **Head of Interventional Pulmonology Unit**, Department of Experimental and Clinical Medicine, Careggi University Hospital, Florence, Italy

Other Activities and positions

1. **Steering Committee Member:**
 - a. 01/2014-2017 PASSPORT, Post market access study sponsored by Roche. PIPF 025. NCT02699879.
2. **Study Review Board Member:**
 - a. 2010-2011, RESOLVE project, funded by the European Commission under FP7-HEALTH-F4-2008 Contract no. 202047
3. **Representative Member:**
 - a. 15/6/2016-1/3/2020 ERN-LUNG group (European Network of Rare Disease) for the Pulmonary Unit, Forlì, IT
 - b. 04/2016-currently, Global IPF Network, University of Colorado, USA
4. **Pharma industry consultant:**
 - a. 2011-currently, Intermune and Roche
 - b. 10/2014-currently, Boeringher-Ingelheim

Professional Societies

1. Member:

- a. 2010- currently, European Respiratory Society
- b. ERS – Interstitial Lung Disease Study group 1.5
- c. 2012-currently, ITS Italian Thoracic Society (former AIPO, Associazione Italiana Pneumologi Ospedalieri)
- d. 2019-currently, EABIP and WABIP member

2. Evaluation Committee Reviewer:

2013- 2020 European Respiratory Society Fellowship

2021-ongoing ERS Guidelines task force

3. Group Leader:

- a. 10/2013-10/2017, Interstitial Lung Diseases and Pulmonary Hypertension Study Group, AIPO – Ass Italiana Pneumologi Ospedalieri
- b. 2020-currently Italian Bond Member Representative for the EABIP (European Association of Bronchology and Interventional Pulmonology).

Major Administrative Leadership Positions

1. 2009- 2014 Leader of IPF Clinic Pulmonary Medicine Unit, GB Morgagni Hospital, Forlì, Italy
2. 2015- 2018 Leader of ILD Clinic (AIMART), Pulmonary Medicine Unit, GB Morgagni Hospital, Forlì, Italy
3. 2018-12/2019 Leader ILD clinic (AIMART), AUSL Romagna, Italy
4. 13/12/2019-29/2/2020, High Specialization in ILDs, Leader of the official Romagna ILD net , AUSL Romagna, Italy
5. **1/3/2020-currently Head of Interventional Pulmonology** Unit, Department of Experimental and Clinical Medicine, **Careggi University Hospital, Florence, Italy**

Management Qualifications

1. 11/2018-03/2019, Leadership e Management delle Malattie Respiratorie, Bocconi University, Milan, IT
2. 2020/2021, master in Management of Healthcare Administration, Bologna University, IT

Editorial Activities

1. Editor in Chief:

- a. 2018-currently, Sarcoidosis Vascular and diffuse lung disease journal

2. Member of the Editorial Board:

- a. 07/2020-currently, BMC Pulmonary Medicine
- b. 2012-2017, Rassegna di Patologia dell'Apparato Respiratorio

3. Reviewer:

- a. 2013, Human Immunology
- b. 2013-currently, Human Immunology, BMC Pulmonary Medicine

- c. 2014-currently, Respirology, Respiratory research,
- d. 2015-currently, European Respiratory Journal, Case Report in Pulmonology,
- e. 2016-currently, Chest, Therapeutic Advances
- f. 2018-currently, Journal of Thoracic Diseases, European Respiratory Review, Canadian Respiratory Journal
- g. 2019-currently, AJRCCM, Int J of tuberculosis and lung diseases.
- h. 2020-currently, Mayo Clinic Proceedings, E-Biomedicine journal
- i. 2020-currently Annals American Thoracic Soc journal
- j. 2020-currently Orphanet Journal of Rare Diseases
- k. 2021-currently The Lancet Respiratory Medicine

Honors and Prizes

1. 6-Dec- 2010, Robalo Cordero Award, 26th Congress of Portugese Resp Soc, Coimbra, Portugal, Research Project : “IPF: from environment to genetic”
2. 7-Jun-2013, Best Poster Award, 6th International WASOG Conference in Paris, Poster title “The diagnostic role of TBLC in the MD of IPF”.
3. 14-Feb-2018, Best publication 2018 Award, Area Vasta Romagna. Publication title “Bronchoscopic Lung Cryobiopsy Increases Diagnostic Confidence in the Multidisciplinary Diagnosis of Idiopathic Pulmonary Fibrosis” AJRCCM 2016

Grant recipient and Principal Investigator

1. 12/2017, Investigator Initiated Study (IIS) funded by Roche and AMMP (Ass Morgagni Mal Polmonari). Title: 15 years of real life data to study the shifting mortality scenario of IPF Retrospective study evaluating factors that have impacted and changed IPF prognosis. Grant 80,000 euros.

Report of most relevant Funded Projects

- **Principal Investigator:**

1. 2012-2019, INPULSIS-ON An open label extension trial of the long term safety of oral BIBF 1120 patients with Idiopathic Pulmonary Fibrrosis (IPF) NCT01619085
2. 2013-2016, RAINER Efficacy and Safety of GS-6624 in subjects with Idiopathic Pulmonary Fibrrosis GS – US – 322-0207. NCT01769196.
3. 2014-2018, Efficacy and Safety of LEBRIKIZUMAB in patients with idiopathic pulmonary fibrrosis. GB28547. NCT01872689. EUDRACT NUMBER: 2013-001163-24
4. 2016-2018, "IPF Italian Observational Study (FIBRONET) " (Boehringer Ingelheim). NCT02803580
5. 2016-2018, INSTAGE - BIBF 1199.36. NCT02802345. EUDRACT NUMBER: 2015-002619-14
6. 2016-2018, ML39260 IRENE, Roche.
7. 2016-2019, MA29957, Roche, NCT02951429 EUTRACT NUMBER : 2015-005131-40.
8. 2017-2019, PF-ILD TRIAL. BIBF 1199.247 Identifier: NCT02999178Sponsor: Boehringer
9. 2017-2019, MA39189 ClinicalTrials.gov Identifier: NCT03099187. Roche.***National Coordinator**
10. 2018-2020, CVAY736X2207 NCT03287414. Novartis.
11. 2018-2020, PF-ILD OPNE LABEL EXTENSION, BIBF 1199.248. Boehringer

12. 2019-2020, Galapagos GLPG1690-CL-303 Phase 3. EudraCT No.: 2018-001405-8
Sponsor: Galapagos
13. 2019-2020, Galecto Biotech, Galactic-1 Sponsor: Galecto Biotech. NCT03832946 .
2018-002664-73 (EudraCT Number)
14. 2021-ongoing Safety of PRM-151 in IPF, phase III trial, Sponsor: Roche.

- **Sub-Investigator:**

1. 2005-2006, INSPIRE Trial, Phase III, NCT00075998
2. 2006-2009, CAPACITY trial, Phase III, NCT00287729
3. 2018-2020, SPIRIT TRIAL. Biogen 203pf203 “Spirit” A Randomized, IIb phase
BG00011 in IPF. ClinicalTrials.gov Identifier: NCT0357350. EUDRACT 2017-003158-
18. Biogen.
4. 2010, ARTEMIS IPF, Phase III, NCT00768300.
5. 2011-2012, INPUSLIS Trial, Phase III, NCT01335464.
6. 2011-2014, AE-IPF, Funded by European Commission, E-rare2, JTC 2011.

- **Study Coordinator:**

1. 2008-2009, BUILD-3 trial, phase III, NCT00391443

- **EU funded projects:**

1. 2020-2023 Dragon consortium: contributor with a study investigating the role of BAL and EBA in COVID-19 diagnosis. Title "Combined data analysis to define clusters of clinical presentation, severity and prognosis of COVID-19. " Approved Ethics Committee : Comitato Etico Regionale per la Sperimentazione Clinica della Regione Toscana Sezione: AREA VASTA CENTRO il 10/11/2020 Protocollo num 18099_bio). (ongoing)

Report of most relevant unfunded projects

- **Principal Investigator:**

1. The diagnostic role of transbronchial biopsy in UIP. Retrospective, monocentric. Approved Ethics Committee : 22/06/2010 Nr. 1493/2010 (Published)
2. Pulmonary manifestations of Birt-Hogg-Dubè syndrome Retrospective Study Approved Ethics Committee : 25/08/2010 Nr. 2613/2010 (Published)
3. Familial Interstitial Pneumonia Profile Retrospective Study Approved Ethics Committee : 26/08/2010 Nr. 2611/2010 (Published, Feb 2014)
4. Anticoagulant therapy for Idiopathic Pulmonary Fibrosis Retrospective Study Approved Ethics Committee : 29/10/2010 Nr. 3327/2010 (Published)
5. The diagnostic role of Cryobiopsy in the multidisciplinary diagnosis of fibrotic interstitial lung diseases Retrospective Study in two steps. Phase one: safety and feasibility. Phase two: MDD. Approved Ethics Committee : 27/06/2013 Nr. 3106/2012 (Phase I: published; Phase II :published)

6. Chest US post criobiopsy for the detection of PNX Prospective, monocentric. Approved By CEROM 2015. (Published).
7. Historical Eye on IPF. Retrospective monocentric. Sponsored by Roche and AMMP. Approved by CEROM prot n 8571/2017, I.5/250 del 13-12-2017. (ongoing)
8. Cryo III. Prognostic validation of TBLC in IPF diagnosis. Retrospective, monocentric. Approved by CEROM prot n 7732/2018, I.5 /247, seduta del 17-10-2018. (published)
9. Clinical and prognostic significance of circulating autoantibodies in Idiopathic Pulmonary Fibrosis. Retrospective Monocentric Study. Approved by Ethics Committee n.2575 del 18.12.2019 prot IPAF di AUSL Romagna. (submitted)
10. **PCOILS**: post COVID19 interstitial lung syndrome, radiologic pathologic correlations obtained by HRCT and TBLC. **Prospective multicenter national study** on cryobiopsy in post COVID fibrosis. 11 Italian participating centres. Approved Ethics Committee : Comitato Etico Regionale per la Sperimentazione Clinica della Regione Toscana Sezione: AREA VASTA CENTRO il 25/09/2020, prot 18098_oss. (ongoing) ***National coordinator**
11. COVID-19 the BAL role in BAL in diagnosis of suspected COVID-19 with negative nasopharyngeal swabs, entitled: "Diagnostic accuracy of the clinical-HRCT diagnosis of COVID-19 in patients with negative nasopharyngeal swabs RT-PCR." **Multicenter retrospective** study. 2 Italian participating centres. Approved Ethics Committee : Comitato Etico Regionale per la Sperimentazione Clinica della Regione Toscana Sezione: AREA VASTA CENTRO il 30/06/2020 Protocollo num 17624_OSS). (ongoing)
12. CRYO IV, study on TBLC in ILDs entitled "Clinical and management implications of histologic information provided by TBLC in ILDs". Substudy of CRYO III CEROM approval prot n 7732/2018, I.5 /247; CEROM approval for CRYO IV date 12/6/2020, numero 4795/2020/15/149 (presa d'atto). (submitted)

- **Participating Centre in multicenter international unfunded studies:**

1. A simple, clinically relevant staging System for Idiopathic Pulmonary Fibrosis Retrospective International Multicenter Study Approved Ethics Committee : 08/04/2011 Nr.1385/2011 (Published)
2. Superdimension and TBLC for the diagnosis of ILDs. Retrospective, multicentric international pilot study. Coordinating center: Aarhus University, Denmark. prot num 19916_oss; authorization Az Careggi, prot 17355 year 2021, 21-7-2021. (published)

- **Co – Investigator:**

1. Is Medical Thoracoscopy indicated in the management of Multiloculated and Organized Thoracic Empyema? Retrospective Monocentric Study Approved Ethics Committee : 05/09/2011 Nr. 3386/2011 (Published)
2. The impact of lung cancer on survival of Idiopathic Pulmonary Fibrosis Retrospective monocentric Study Approved Ethics Committee : 26/08/2012 Nr. 2611/2012 (Published)
3. Sleeping Disorders in IPF (DRS in IPF). Prospective monocentric study. Approved by Ethics Committee (Published).

Report of invited oral presentations

• **International:**

1. 24 May 2012 Genetic determinants of Familial Pulmonary Fibrosis. Developmental Pulmonology Laboratory Research Conference. Department of Pediatrics, S Francisco General Hospital, UCSF, CA, USA.
2. 30-Nov-1Dec, 2012, Interactive Clinical Cases. Working together to translate IPF research into practice. European AIR Meeting, Rome, Italy.
3. 5June2013, The role of TBLC in the multidisciplinary diagnosis of IPF. Wasog Meeting. Paris, France*Recipient of the Wasog Best Poster Presentation Award
4. 9-10 June 2014 The role of TBLC in MD diagnosis of IPF. Transbronchial lung cryobiopsy. ERS endorsed course. Ravenna, Italy
5. 6-10 Sept 2014, Patient cases: the multidisciplinary approach Evening Symposium : How to diagnose and treat IPF: learnings from clinical and real-world experience ERS annual congress. Munich. Germany
6. 27 Sept, 2015 “Educational skills workshop: EW10 Radiological – pathological correlations for clinicians”; Workstation 2: Interstitial fibrosis; ERS annual Congress, Amsterdam, Netherlands
7. 27 Nov, 2015 “MDT case in Session 2: Striving for early IPF diagnosis” Air Meeting International. Prague, CZ
8. 12 March, 2016 Transbronchialcryobiopsy in ILD, overview and update, presented with Prof. T.V. Colby, Mayo Clinic ,AZ USCAP Annual Meeting, Seattle, WA, USA
9. 16 March, 2016 Transbronchialcryobiopsy in ILD, overview and update. Pulmonary Fellow Wednesday Morning Meeting, Mayo Clinic ,AZ
10. 16 March, 2016 Transbronchialcryobiopsy in ILD, overview and update Pulmonary Meeting, Phoenix Hospital, AZ
11. 8-11 May, 2016 “Multidisciplinary diagnosis” World Congress for Bronchology and Interventional Pulmonology. Florence, IT
12. 1-4 June, 2016 8th international WASOG conference. Gdnask, PolandTransbronchial cryobiopsy in diffuse parenchymal lung diseases. Case presentation clinical round
13. 2-7 Sept 2016 ERS Annual Congress. London, UK.
 - a. Skills workshop: SW20 Radiological-pathological correlations for clinicians. Workstation 2: Interstitial fibrosis
 - b. Year in review: Clinical year in review Diffuse parenchymal lung disease. Session 51
14. 17-19 Nov, 2016 “ BLC for the diagnosis of IPF” Advancing IPF Research (AIR) Educational Meeting. Vienna.
15. 22 Feb, 2016 “ Transbronchial lung cryobiopsy in idiopathic interstitial pneumonia: state of the art “ Workshop: a new era for IP. Leuven, Belgium
16. 23 Feb, 2016 “Clinical diagnostic value of bronchoscopy in IIP “ Interventional Pulmonology symposium. Leuven, Belgium
17. 9-13 Sept, 2017. Speaker and tutor: “Skills workshop: SW20 Radiological-pathological correlations for clinicians. Workstation 2: Interstitial fibrosis. ERS, Milan, IT
18. 10-11 Oct, 2017. Course: Transbronchial cryobiopsy in DLPD “ endorsed by ERS, Ravenna, IT
 - a. “Cryo-TBB vs awakened VATS
 - b. “IPF therapy : the future
 - c. Chair of the session: “Technical notes. TBCB: how should be done”

19. 15-18 Nov, 2017. 17° Congresso paulista de Pneumologia e Tisiologia, sao Paulo, Brazil Speaker: “Cryobiopsy and ILD”
20. 14-15 Dec, 2017 Con debate: “IPF should be viewed as a malignancy, based on pathogenesis, biomarker signal and disease behaviour” International summit for ILD, ERICE study group, ERICE, IT
21. 7-9 June, 2018. “Interstitial Lung Abnormalities” WASOG annual meeting, Crete, GR
22. 14-19 Sept, 2018. ERS annual meeting, Paris, FR. Lectures:
 - a. “Acute Interstitial Lung Diseases”, PG course, September 15
 - b. “Interstitial Fibrosis”, Skill workshop, September 18
 - c. “IPF treatment” , Speakers dinner Roche Brasil, September 16
23. 26-27 Sept, 2018 Lecture: “Nintedanib for IPF treatment” Cryobiopsy International Meeting, Ravenna, IT
24. 11-12 Oct 2018 “NSIP” and clinical cases ILD Network meeting, Lisbona, Portugal (sponsored BI)
25. 17-18 Nov, 2018 “Difficult communications” Advancing IPF Research (AIR) Educational Meeting. Munich, German
26. 22-24 November, 2018. Think Lung, Bahia, Salvador , Brazil. Lectures:
 - a. “Cryobiopsy:where do we stand and where will we go”
 - b. “the utility of cryobiopsy for the diagnosis of ILDs”
 - c. IPF diagnosis and treatment, panel discussion
 - d. Clinical Cases
27. 15 March, 2019 “Pathologic diagnosis of Idiopathic Pulmonary Fibrosis: Which is the role of the cryobiopsy?” International symposium of ILDs, Barcelona, Spain
28. 27 Sept-1o oct, 2019. ERS Annual Congress, Madrid , Spain:
 - a. Endoscopy Live session on lung transbronchial cryobiopsy in ILDs
 - b. Post graduate course on Pulmonary endoscopy, Cryobiopsy in patients with interstitial lung diseases.
29. 7-9 Nov, 2019. 35th Portuguese Pulmonary Society Annual Congress, Albufeira, Portugal. Lecture title: How to predict progression, when and how should we treat?
30. 15-16 Nov, 2019. AIR Europe, Malmo, Sweden. Lecture title: Examining ILAs and their significance to development of ILD
31. 4 June 2020. ERS web course COVID-19 and the management of Interstitial Lung Diseases patients: challenges and recommendations
32. 18 June 2020, Escubriendo Encognita en el entorno COVID-19, Spain (web). Lecture: COVID-19 and ILD.
33. 20 June, 2020. "Challenges and recommendations in the management of Chronic Respiratory Diseases and the COVID-19 disease" (web). Lecture “Novel data in interventional pulmonology”.
34. 20 June, 2020. International web course (ALAT, ITS, Sociedad Espana, SPPecc). "Challenges and recommendations in the management of Chronic Respiratory Diseases and the COVID-19 disease" lecture title: “Novel Data in interventional Pneumology”.
35. 5-9 Sept, 2020. ERS international congress, on-line:
 - a. Oral poster presentation: Historical eye on IPF: redefining the mortality scenario
 - b. The hot and the cold of interventional pulmonology, oral poster presentation: "Clinical management implications of histologic information provided by lung biopsy in the multidisciplinary evaluation of interstitial lung diseases."
 - c. Lecture: Lung transplant in ILDs
36. 12 Nov, 2020. Albufeira (on-line). FIBROTIC PULMONARY INTERSTITIAL LUNG DISEASES Lecture: Early Diagnosis of Fibrotic Pneumonias and the impact on Clinical Management.
37. 15-16 Nov, 2019. AIR Europe. Malmo, Sweden. “Interstitial lung abnormalities”.
38. 27-28 May, 2021. Romanian National Congress. Lecture: “post-COVID-19 ILD”.
39. 14-17 July, 2021. Oporto ILD meeting, Portugal (web). Lectures: “Hypersensitivity pneumonitis” and “PPFE”.

- **National:**

1. 20-22 Oct 2008 Usual Interstitial Pneumonia Advanced Course. HRCT of the thorax. Arezzo
2. 2-5 Dec 2009, AIPO National Pulmonary Congress, Milan Convention Center, ITALY:
 - a. Idiopathic Pulmonary Fibrosis
 - b. Anti TNF treatment for ILDs-related to connective tissue diseases.
 - c. Birt Hogg Dubè Syndrome
3. 19 June 2009, Aggiornamenti in Med Interna. Bari, IT. Title: Diagnosis of ILDs
4. 15-17 April 2010, Corso teorico-pratico. Interstiziopatie polmonari. Gubbio, IT. Lectures:
 - a. Clinical profile of diseases with HRCT Reticular Patterns
 - b. Clinical Cases
5. 10-12 May 2010 Idiopathic Pulmonary Fibrosis ERS scientific group on DPLD post graduate course, PneumoTrieste, Trieste, ITALY
6. 25-26 Nov 2010 Birt Hogg Dubè Syndrome, the pulmonologist point of view Giornata di Informazione sulla sindrome di Birt Hogg Dubè. Az Osp S Croce Carle, Cuneo, ITALY
7. 1 Dec 2010 Clinical case of Sarcoidosis Le Malattie Rare del Polmone. Modena Univeristy, Modena, Forlì ITALY
8. 4-6 April 2011 Practical approaches to Idiopathic Pulmonary Fibrosis ERS scientific group on DPLD post graduate course, PneumoTrieste, Trieste, ITALY
9. 30Nov-3Dec 2011 Evoluzione e storia naturale delle pneumopatie interstiziali - IPF e cancro XII National Congress UIP, Bologna, ITALY
10. 26-28 March, 2012 Clinical differential aspects of IPF.
11. 12-14 April, 2012 ERS course at PneumoTrieste Annual Meeting, Trieste, ITALY Lectures: A) Fibrosi Polmonare Idiopatica : la clinica. B) Le pneumopatie infiltrative diffuse: nuove acquisizioni. Villanovaforru, Cagliari.
12. 3-5 May 2012 Le PID con pattern reticolare III post graduate course: le PID conoscere per riconoscere. Gubbio, Italy.
13. 26-27 Oct, 2012 Pirfenidone Named Patient Program. AIR Meeting Italia. Rome, Italy.
14. 8-10 April, 2013 Different clinical profiles of IPF. ERS course at PneumoTrieste Annual Meeting, Trieste, ITALY
15. 17 April, 2013 La clinica delle interstiziopatie polmonari. Corso di patologia pleuro-polmonare. Dipartimento Anatomia Patologica, Università degli Studi di Verona, Italy.
16. 27 April, 2013 Criobiopsia Sorrento Breathing, Sorrento, Italy.
17. 7-9 Maggio, 2013 La IPF: la clinica Pneumopatie infiltrative diffuse, asma e BPCO. Villanovaforru, Cagliari, ITALY
18. 28-29 June, 2013 L'esperienza NPP in Italia: cosa abbiamo imparato. AIR MEETING ITALIA 2013. Milano, Italy.
19. 7-9 April 2014 Idiopathic Pulmonary Fibrosis, clinical aspects
20. ERS scientific group on DPLD post graduate course, PneumoTrieste, Trieste, ITALY
21. 7-8 June 2014 Novel Therapies for IPF. Asthma, IPF and other ILDs. Assisi, ITALY
22. 27-28 June, 2014 IPF, mystery case AIR MEETING ITALIA 2014. Rome, Italy.
23. 1-3 oct, 2014 Update on ILD. FIP, National Pulmonology Congress, Genova, Italy.
24. 8-11 Sept ,2014 La clinica delle interstiziopatie polmonari. PneumoCampania 2014 - 7^a edizione Vietri sul Mare, Italy.
25. 23-25 Oct 2014 Clinical cases on ILDs III post graduate course: le PID conoscere per riconoscere. Gubbio, Italy.
26. 28-29 Nov, 2014 "Clinica e terapia della IPF;" Updates in Pneumologia, Cosenza, Italy
27. 5-6 Nov, 2014 Staging e FU della IPF, IPF workshop, Palermo, Italy
28. 7-8 Nov, 2014 "IPF aspetti clinici e terapeutici"; Convegno interregionale ASPAM Terni, IT

29. 14-15 Nov, 2014 “Diagnosi della IPF con tecniche invasive”; AIPO Toscana, Massa Carrara, IT
30. 5-6 Feb 2015 “Le metodiche invasive”; Orizzonti in pneumologia, Verona, IT
31. 13-15 April 2015 “PPFE, NSIP, HP”; Pneumotrieste 2015, Trieste, IT
32. 9 May, 2015 “Grande fornitore di UIP”; 20anni di trapianto, Padova, IT
33. 29-30 May, 2015 “DIAGNOSIS OF PULMONARY FIBROSIS, WHAT’S NEW?”; he Missing Links, Roma, IT
34. 25-26 June, 2015 “End point dei trial clinici nella IPF, cosa migliorare”; Air meeting Italia, Roma, IT
35. 2 Oct, 2015 “Clinical case”; LA DIAGNOSI MULTIDISCIPLINARE E LE SCELTE TERAPEUTICHE DELLE PID e IPF; Firenze, IT
36. 9-10 Oct, “IPF:an heterogeneous entity”; AIPO Lazio, Nemi, Roma, IT
37. 16-17 Oct, “IPF profile clinic e stadiazione”; IPF next generation, Matera, IT
38. 19 Oct, 2015 “IPF”; Confidence, Trieste, IT
39. 6 Nov, 2015 "I misteri delle malattie dell'interstizio polmonare ed i segreti del ventricolo destro" San Daniele del Friuli, Udine, IT
40. 11-15 Nov, 2015 AIPO, Annual National Congress. Naples, IT:
41. 12-14 Nov AIPO National Annual Congress. Naples, IT, “Highlights dalle recenti linee guida/raccomandazioni nazionali ed internazionali 13 Nov, “Common Variable Immunodeficiency” 14 Nov, “IPF treatment”
42. 11, Dec 2015 “Biopsia per via endoscopica o chirurgica?” Pneumoroama , Roma, IT
43. 12, Dec 2015 “UIP il punto sul Pirfenidone e le nuove terapie” Updates in Pneumologia. Mendicino, CS, IT
44. 10 April, 2015 PIDAIPO giovani, Bologna, IT
45. 5-6 June, 2015 “L’imaging come guida alle procedure endoscopiche”; AIPO Pneumo Interventistica; Bologna, IT
46. 13 June, 2015 “New mini invasive diagnostic techniques”; MAR, Modena, IT
47. 21—22 Jan, 2016 “La fibrosi polmonare idiopatica: patogenesi e terapia” Bari Pneumologica. Bari, IT
48. 18-20 Feb, 2016 “Lo Pneumologo: il nuovo documento AIPO-SIMeR” Il futuro della pneumologia... la pneumologia del future. Lecce, IT
49. 12-13 April, 2016 “New frontiers. Early IPF” ERS course DPLD. Respiro Trieste. Trieste, I
50. 14-15 April, 2016 “La terapia medica della fibrosi polmonare idiopatica: passato, presente e futuro” Aggiornamento sulle patologie polmonari. Taranto, IT
51. 16 April, 2016 “Biomarkers: quale utilità ai fini diagnostici, prognostici e di risposta alle terapie” Innovazione ed organizzazione in pneumologia. Matera, IT
52. 20 April, 2016 “Attualità in tema di IPF” Congresso sez regionle AIPO ER. Baggiovara, Modena, IT
53. 28-30 April, 2016 “Le Infezioni disseminate” Le pneumopatie interstiziali diffuse. Gubbio, IT
54. 6 May, 2016 “Dagli elementi anatomo-patologici all’Imaging. Quali certezze per il clinico?” Col fiato corto 6. Palermo, IT
55. 27 May, 2016 “Fibrosi e granulomatosi polmonare da droghe” 11° Pneumosalento. Lecce, IT
56. 17-18 June, 2016 “Terapia dell’IPF” La criobiopsia nella patologia parenchimale diffusa. Genova, I
57. 23-25 June, 2016 “I marcatori di patologia nell’IPF: molecolari, funzionali, clinico-radiologici” AIR Meeting National. Baveno, IT
58. 7-8 Oct, 2016 “La gestione diagnostica dei casi “difficili” e il ricorso alla biopsia: quando è necessaria una diagnosi istologica e come eseguirla”. Le pneumopatie infiltrative diffuse. Chieti, IT
59. 8 Nov, 2016 “Criobiopsia La patologia toracica di interesse chirurgico e medico: le convergenze parallele. Verona, IT

60. 11 Nov, 2016 “Nuove linee guida nazionali ed internazionali della IPF: similitudini differenze” AIPO regione Marche. Civitanova Marche, IT
61. 15-17 Dec, 2016 “Markers molecolari della IPF e dei suoi mimickers” Pneumoroma. Roma, IT
62. 2-3 Jan, 2017 “La terapia della NSIP Orizzonti in Pneumologia. Verona, I
63. 31 March-1 April, 2017 Il trattamento «ritardato» nell’IPF è ancora accettabile? Oxford Debate AIR Meeting Italy, Bologna, IT
64. 3-5 April, 2017 “ILA prevalence and clinical relevance” ERS course DPLD. Respiro Trieste. Trieste, IT
65. 10 e 31 May, 2017 speaker and tutor Sliding Doors course for pulmonologists, Padova, IT
66. 26-27 May, 2017 Speaker: “La criobiopsia nella diagnosi dell S.S.D. PNEUMOLOGIA^[L] Settore Aggiornamento e Formazione INTERNATIONAL CONGRESS, Courmayeur, Aosta IT
67. 10-13 June, 2017 Speaker: “PID Acute” 12 June Chair: “Granulomatosi polmonari” 13 June AIPO, National Congress of Italian Pulmonology, Bologna, I
68. 16-17 June, 2017 Speaker: “Pattern fibrosante: quando è IPF”, and clinical cases presentation Fibrosing lung diseases a MD approach, Ancona, IT
69. 4- Nov, 2017 Course: La fibrosi polmonare idiopatica, Brindisi, IT
Lectures: “Meccanismi patogenetici e correlazioni radiologiche e patologiche” “Il profilo della early IPF”
70. 30 Aprile, 2017 “PID: approccio diagnostico” Course: XIV corso teorico-pratico Pneumologia Interventistica, Parma, IT
71. 1-2 Feb, 2018 Lecture: “IPF e tumore polmonare: modalità di gestione dell’esperienza clinica” IPF Connect, Ancona, IT
72. 21 Febbraio 2018 L’esperienza del centro di Forlì Confronto delle esperienze real life, Torino, IT
73. 9 March, 2018 Lectures: “Esperienza del centro di Forlì” Gli esperti a confronto, Padova, IT
74. 3-5 May, 2018 Lectures: “Early IPF, a progressive disease to treat” The pathogenesis of COPD and IPF, Florence, IT
75. 5-26 May, 2018 Lectures: “Pattern fibrosante quando è IPF” “La terapia della IPF” Fibrosing Lung Diseases, Ancona, IT
76. 3-5 May, 2018 Lectures: “Early IPF, a progressive disease to treat” The pathogenesis of COPD and IPF, Florence, IT
77. 22-23 June, 2018 Lecture: “I punti fermi dello pneumologo, diagnostica e decisione terapeutica” AIR meeting Italia, Baveno, IT
78. 22 Sept, 2018 Lecture “IPF” Giornata mondiale della IPF, Pistoia, IT
79. 1 October, 2018 Lecture: “Treatment of IPF” and “Clinical cases” Transbronchial Cryobiopsy a course for pathologists, Milan, IT
80. 4 October, 2018 lecture: “Comorbidità e IPF” La gestione multidisciplinare delle PID, Foggia, 4 Ottobre 2018
81. 21 Dec, 2018 Lecture: “pattern fibrosante” e “Terapia della IPF, Bologna IT
82. 13-15 Dec, 2016 “Terapia delle interstiziopatie quasi IPF” Pneumoroma. Roma, IT
83. 18 Gennaio 2018 L’esperienza del centro di Forlì Confronto delle esperienze real life, Torino, IT
84. 13-15 Febbraio, 2019 “Terapia della IPF” EURX 6° Incontro, Bolzano, IT
85. 1-3 April, 2019 “Mystery case” PneumoTrieste, Trieste, IT
86. 14-15 June, 2019. AIR Italy national meeting, Turin, IT. Lecture: IPF and lung cancer
87. 6-7 Sept, 2019. World Scleroderma Lung Foundation, ILD-SSc master class. Lecture: Is lung biopsy necessary today in ILD?
88. 13-16 Nov, 2019. AIPO National congress. Lectures:
 - a. TBLC: validation for diagnosis and prognosis of iILDs
 - b. Linee guida: stesura e significato
89. 13 Dec, 2019. PneumoRoma. Lecture: IPF in 2019.

90. 18-19 Oct, 2019, Naples, IT. ILD Vernissage. Nuove metodologie diagnostiche in ILD
91. 24-25 Jan, 2020. Bologna, IT. Pneumopatie diffuse fibrosanti e non. Lecture: Proseptive terapeutiche PID Fibrosanti.
92. SIP and AIPO, Italian IPF Guidelines National Event (multiple events):
 - a. Lecture: Invasive diagnosis of IPF. 31 Jan 2020, Milan IT.
 - b. Lecture: IPF diagnosi differenziale e inquadramento. 30 Sept, 2020 – on line
 - c. Chair and speaker, AIPO Toscana. IPF diagnosis. 12 Nov, 2020.
93. 7 Feb, 2020. Turin, IT. Terapie IPF. Lectures: 1) “News ATS-ERS”, 2) Early IPF treatment.
94. 14 Feb, 2020. Turin, IT. Role of awake biopsy in PID. Lecture: Awake biopsy and cryobiopsy comparison.
95. 18 June, 2020. Reggio Emilia web course: ipotesi patogenetiche di danno sub-acuto polmonare in pazienti post COVID19
96. 18 Sept 2020, Transbronchial lung cryobiopsy ERS-AIPO course. Web. Lecture: TBLC diagnostic and prognostic impact.
97. 29-30 Sept, 2020. IPF and friends, AIPO on-line event. Lecture title: “IPF: Terapia, an Update”.
98. 5-7 Oct, 2020. Respiro Trieste (on-line). Lectures: “Current and future treatment SSc-ILD”; “Cryobiopsy pro”.
99. 7 Oct, 2020. OMAR, on-line event. Lecture: Autoimmunity, Scleroderma and lung involvement.
100. 23 Oct, 2020. ERN lung, Pavia (on-line). Lecture: “S interstiziale post COVID-19: nuova o vecchia ILD?”.
101. 4-5 May, 2021. PF-ILDs. SIP course (web). Lecture: “Lung biopsy in ILDs”.
102. 14-19 May, 2021 ATS (web). Oral Poster Presentations: “PCOILS, preliminary results from a National prospective study on post COVID-19 ILD” and “A pilot study on EM navigation and cryobiopsy in ILDs”.
103. 22 May, 2021. World Scleroderma Foundation meeting. Brazil (web). Lecture: “Bronchoalveolar lavage and the biopsy for ILD: respective indications and input”.

• **Local events, 2008-2019 Emilia-Romagna:**

1. 15-16 Sept 2006 Clinical Case - Lymphoproliferative Lung Disorders Ematologo e Pneumologo Congress – GB Morgagni Hospital, Forlì, ITALY
2. 26-27 Jun 2007 Lung Lymphoproliferative Disorders Pneumopatie infettive e pseudoinfettive. GB Morgagni Hospital, Forlì Giugno ITALY
3. 13 Nov 2007 Lymphoproliferative disorders: the role of pulmonology Stage in Ematologia: linfomi polmonari, i progressi della conoscenza. Università Studi di Bologna, Bologna ITALY
4. 27-28 Nov 2007 Idiopathic Pulmonary Fibrosis Corso teorico-pratico. Interstiziopatie polmonari. GB Morgagni Hospital, Forlì ITALY
5. 4-8 Feb 2008 Idiopathic Pulmonary Fibrosis Corso residenziale. Interstiziopatie polmonari. GB Morgagni Hospital, Forlì ITALY
6. 26-27 Jun 2008 Lung Lymphoproliferative Disorders Pneumopatie infettive e pseudoinfettive. GB Morgagni Hospital, Forlì Giugno ITALY
7. 15-19 Sep 2008 Idiopathic Pulmonary Fibrosis Corso teorico-pratico. Interstiziopatie polmonari. GB Morgagni Hospital, Forlì ITALY
8. 25-27 Jan 2010 Idiopathic Pulmonary Fibrosis Corso teorico-pratico. Interstiziopatie polmonari. GB Morgagni Hospital, Forlì ITALY
9. 18 May 2010 Oxygen therapy in IPF Corso teorico-pratico. Hospice, Forlimpopoli, ITALY
10. 14-16 June 2010 Idiopathic Pulmonary Fibrosis Corso teorico-pratico. Interstiziopatie polmonari. GB Morgagni Hospital, Forlì ITALY
11. 13-15 Dec 2010 Idiopathic Pulmonary Fibrosis, Corso teorico-pratico. Interstiziopatie polmonari. GB Morgagni Hospital, Forlì ITALY

12. 16 Dec 2010 Therapeutic approaches of Idiopathic Pulmonary Fibrosis RIPID workshop. Fibrosi ed ipertensione polmonare. GB Morgagni Hospital, Forlì ITALY
13. 28-29 Feb 2012 1) La clinica della IPF, 2 La terapia della IPF. Corso: La Fibrosi Polmonare Idiopatica. GB Morgagni Hospital, Forlì ITALY
14. 5-7 March 2012 1) La Fibrosi polmonare Idiopatica 3) Le vasculiti Corso: Le Pneumopatie infiltrative diffuse. GB Morgagni Hospital, Forlì ITALY
15. 30 October, 2012 Corso : La Fibrosi Polmonare. GB Morgagni Hospital, Forlì ITALY
16. 19-20 Feb, 2013 1 La clinica della IPF 2 La terapia della IPF Corso: La Fibrosi Polmonare Idiopatica. GB Morgagni Hospital, Forlì ITALY
17. 20-22 March, 2013 La Fibrosi polmonare Idiopatica Corso: Le Pneumopatie infiltrative diffuse. GB Morgagni Hospital, Forlì ITALY
18. 10-12 April, 2013 1) La clinica della IPF La terapia della IPF Corso: le Pneumopatie Infiltrative Diffuse. GB Morgagni Hospital, Forlì ITALY
19. 9 Dec 2013 La Fibrosi polmonare Idiopatica Corso Speed-it. GB Morgagni Hospital, Forlì ITALY
20. 24 Jan 2014 Diagnosis and treatment of DPLDs. Corso Insuff Respiratoria. Museo Internazionale delle ceramiche, Faenza, ITALY.
21. 27-28 March 2014 IPF, Clinical Cases presentation. CSI in IPF, Cube Hotel, Ravenna, ITALY.
22. 3-4 Feb, 2015 Clinica della IPF Corso IPF, Forlì, IT
23. 3-5 March, 2015 Clinica della IPF; Corso PID, Forlì, IT
24. 15-17 June, 2015 “IPF clinica”; Corso AIPO PID, Forlì, IT
25. 8-9 Sept, 2015 “A future view on ILD” and “The MDD in ILD diagnosis”; Cryobiopsy meeting second ed., Ravenna, IT
26. 18 Sept, 2015 “Clinical case”; Convegno nazionale SIRM, Parma, IT
27. 9-11 Feb, 2016 “Clinica della IPF e dintorni” Fibrosi Polmonare Idiopatica. Forlì, FC, IT
28. 7-9 June, 2016 “Fibrosi polmonare idiopatica: clinica” e “Procedure diagnostiche invasive” Corso Pneumopatie infiltrative diffuse. GB Morgagni H, Forlì, FC, IT
29. 3-4 and 24-25 May, 2016 In Hospital Meeting: IPF Excellence. Forlì IT 3 May, “Il profilo clinico della IPF” 4 May “La terapia della IPF” 5 May “La criobiopsia polmonare”
30. 28-19 Oct, 2016 “Treatment of IPF : an update” TBLC in DPLD. Endorsed by ERS. Ravenna,
31. 21 Oct, 2016 Meet the Expert in IPF. Forlì, FC, IT “Opzioni terapeutiche nel trattamento dell’IPF” “Casi clinici multidisciplinari: dalla diagnosi alla cura del paziente con IPF – Esperienze a confronto” “Stars e Black Holes: successi e problematiche irrisolte dei Centri di riferimento. Modelli e risultati organizzativi dei Centri e problematiche gestionali”
32. 19 Oct, 2016 “Ottimizzare la gestione del paziente con BPCO” ECM 38-164989. Forlì, Italy
33. 3 Nov, 2016 “La visione del clinico” “FARMACISTI A CONFRONTO: APPROPRIATEZZA TERAPEUTICA, BUDGET DI SPESA E GESTIONE DELLE GARE” Rimini, I
34. 13-14 Dec, 2016 “La diagnosi differenziale” LA CONDIVISIONE DELLA PRATICA CLINICA NELLA FIBROSI POLMONARE IDIOPATICA. 9 national centres web-connected. Forlì, IT.
35. 14-16 Feb, 2017 “Profili clinici IPF e quasi IPF” and “Early IPF and IPF friends perchè e quando trattare” Course: IPF and friends. Forlì, I
36. 8-9 Maggio, 2017 Lectures: “Opzioni terapeutiche” “Aspetti organizzativi nella gestione del paziente” Tavola rotonda Course: Clinical management of IPF, Ravenna, IT
37. 20-21 June, 2017 Lecture: “IPF” and Chair of the session “Patologia sistemica I” Course: Pneumopatie infiltrative diffuse, Forlì, IT
38. 24 Sept, 2017 Lecture: “ILDs, la gestione del paziente in Italia: differenze tra teoria e pratica clinica” Course: Respirare e Comunicare, Forlì, IT

39. 9-10 Nov, 2017 Lecture: “Novità dai congressi internazionali: aspetti clinici” Course: IPF in Practice personalizzare l’algoritmo terapeutico, Ravenna, IT
40. 22 febbraio, 2018 “Terapia dell’IPF et similia IPF and Friends, Forlì, IT
41. 15-16 March, 2018 Lectures: “La gestione del paziente acuto” “La terapia di IPF e quadri IPF” “IPF e quasi IPF Course: Respirare e comunicare, Forlì, IT
42. 26 e 28 Giugno 2018 Lecture: “Patogenesi del tumore polmonare similitudini con il cancro Pneumopatie Infiltrative Diffuse, Forlì, IT
43. 19-20 Febbr, 2019 “Profilo clinic della IPF” IPF and Friends, Forlì, IT
44. 19-20 Feb, 2019 IPF and friends. AIPO course, Forlì, I
45. 25-27 June, 2019, PID course, Forlì, IT
46. 27 Feb, 27 March, 17 April, 11+25 Oct, 29 Nov, 2019-IPF challenging clinical cases. Forlì IT
47. 24 January, 2020. PID and MDT. Lecture. “treatment of progressive fibrosing ILDs”.
48. 26-27 Nov, 2020 PID. AIPO course, Forlì. Lecture “IPF treatment update”

- **Local events, 2020-currently Florence:**

1. 23 Oct, 2020. Florence, IT (on-line). Unmet needs in thoracic oncology. Lecture: “lung cancer and ILDs”.
2. 24 May, 2021. Florence. PID, Lecture on cryobiopsy in ILDs.
3. 7 June 2021. Florence, IT. L'importanza della multidisciplinarieta' Lectrue on cryobiopsy in ILDs.

Experience in Educational programs and Training

- **International Education Programs:**

1. 3-5 june 2014, 13-15 oct 2014, 20 oct 2014. Perceptorship. International training program for chest physicians on IPF sponsored by Intermune. GB Morgagni Hospital, Forlì, Italy
2. 11-12- Nov 2014. Global internal train the trainer meeting, for pharma industry representatives, sponsored by Boeringher-Ingelheim. Frankfurt, Germany.
3. Nov and Dec 2015. “In-Hospital”, “Tutorship”, “Regional Lab” and “Call Simulations” programs, for pharma industry representatives and pharmacysts sponsored by Boeringher-Ingelheim, GB Morgagni Hospital, Forlì, IT.
4. 12-14 Jan 2016. “In-Hospital” program for pharma industry representatives sponsored by Boeringher-Ingelheim, GB Morgagni Hospital, Forlì, IT.
5. 23-25 Nov, 2016. Perceptorship. International training program for chest physicians on IPF sponsored by Roche. GB Morgagni Hospital, Forlì, Italy

- **Academic Educational Activities:**

- a. **Lessons:**

1. Università Politecnica delle Marche, Dip Scienze Biomediche e Sanità Pubblica, Master Universitario II livello in Pneumologia Interventistica, AA 2018-2019, titolo della docenza “Il BAL: tecnica, indicazioni e risultati” svolto in data 4 Giugno 2019 dalle ore 9.00 alle ore 11.00.
2. Master in Interventional Pulmonology, Florence, Italy - year 2020:
 - a. “Endoscopy and COID-19”
 - b. “TBLC for the diagnosis of ILDs”

3. Medical School, Florence University – year 2020/2021. Topics: Respiratory Diseases (Pleural effusions, Tuberculosis and mycobactriosis, ILDs, signs and symptoms of respiratory diseases)
4. Neurophysiopathology Technicians Specialization School, Florence University – year 2020/2021. Topics: Respiratory Diseases (sleep disorders, respiratory involvement in neuromuscular diseases, sistemic diseases involving brain and lung)
5. Sports medicine, Florence University – year 2020/2021 Respiratory Diseases (Respiratory assessment and physical activity, respiratory diseases and exercise: ILDs, pulmonary vascular diseases and respiratory infections.)
6. Pulmonary Medicine Specialization School, Florence University – year 2020/2021. Topics: respiratory diseases (ILDs and interventional pulmonology).

b. Tutorship and Thesis

1. External consultant: March 2019, Dr. Piera Soggio, PhD thesis in Experimental and Regenerative Medicine ", University of Foggia, IT
2. Co-supervisor: May 2019, Dr. Irene Cardillo, Specialization thesis in diseases of the respiratory system entitled "Idiopathic Fibrosis: new predictors of survival", University of Palermo.
3. Tutor: July 2016, Dr. Dora Nicotra, Specialization thesis in diseases of the respiratory system entitled "Peluroparenchymal fibroelastosis and its mimickers", University of Catania.
4. Supervisor: June 2019, Dr. COLANARDI MARIA CRISTINA born in FOGGIA on 30/06/1975, thesis of II Level Master in Interventional Pneumology at the Polytechnic University of Marche, entitled: "STUDIO DELLE ILAs (INTERSTITIAL LUNG ABNORMALITIES) "
5. Co-chair: 9 july 2021, Dr.ssa Meliante Laura Antonia, Florence School of Medicine, "The role of BAL in the diagnosis of SSc", 110/110 summa cum laude e menzione.

Report of Clinical Activity and Innovations

- **General Pulmonology:**

1. 2007-2013 Inpatients activity, General Pulmonology unit, Pulmonary Unit, GB Morgagni Hospital, Ten weeks per year
2. 2007-2014 Outpatient general Pulmonary Clinic , Pulmonary Unit, GB Morgagni Hospital Twentyfive weeks per year
3. 2013-02/2020 On-call-General Pulmonology Pulmonary Unit, GB Morgagni Hospital
On call once/twice a week and one week-end per month
4. 2007-02/2020 Oncologic Multidisciplinary team participation (GIPO), Pulmonary Unit, Forlì Hospital. One session per week.
5. 1/3/2020-currently. Oncologic Multidisciplinary team participation (GOM), Careggi University Hospital. One session per week.

- **Interstitial Lung Diseases:**

6. 2007-2014 IPF Clinic Pulmonary Unit, GB Morgagni Hospital Three Sessions per week, including clinical activity on lung transplant patients (pre and post transplant).
7. 2015-02/2020 Senior consultant ILD Clinic (AIMART) Pulmonary Unit, GB Morgagni Hospital Five Sessions per week
8. 2007-02/2020 ILD Multidisciplinary team coordination and participation, Pulmonary Unit, GB Morgagni Hospital. One session per week.
9. 1/3/2020-currently. ILDs Multidisciplinary team participation (GIM), Careggi University Hospital. One session per week.

- **Interventional Pulmonology:**

10. 2007-02/2020 Interventional Pulmonology Pulmonary Unit, GB Morgagni Hospital
One/two sessions per week including the following activities: 617 rigid bronchoscopies, both diagnostic and operative; 262 mediastinal lymph node biopsies / aspirates (TBNA, **EBUS-TBNA, EUS-FNA**); 200 **transbronchial biopsies with cryoprobe** (of which the center of Forlì is a pioneer and holder of the largest international case studies with 699 cases published and over 1300 cases carried out); 1,474 flexible bronchoscopies, transbronchial biopsies with conventional probe, with radial EBUS, broncholaveolar washes, bronchial washes and bronchospirations; 73 **medical thoracoscopies, including pediatric cases and empyema management; 1 total lung washing for alveolar proteinosis.**
11. 2007-02/2020 On-call-Interventional Pulmonology Pulmonary Unit, GB Morgagni Hospital
On call once/twice a week and one week-end per month
12. 1/3/2020-currently Interventional Pulmonology Unit, Careggi University Hospital, Five sessions per week including the following activities: rigid bronchoscopies, both diagnostic and operative; mediastinal lymph node biopsies / aspirates (TBNA, **EBUS-TBNA, EUS-B**); **transbronchial biopsies with cryoprobe with fluoroscopy guide, radial EBUS guide and EM navigation (ongoing prospective multicentre study on EM navigation and cryobiopsy)**; flexible bronchoscopies, transbronchial biopsies with conventional probe, with radial EBUS, broncholaveolar washes, bronchial washes and bronchospirations. **Pleural procedures** including thoracentesis and chest tube drainages.

Report of Education of Patients and Service to the Community

2009-29/2/2020 AMMP Associazione Morgagni per le Malattie Polmonari

One of the founders and an active member of this organization that promotes information about lung health in the local community and supports research and educational programs in the field of rare lung disorders.

Orgazizer and promoter of the events entitled “Il rinforzo della trama”, educational activities dedicated to patient associations and local pulmonary physicians

14/09/2014 “ Il rinforzo della trama I ed”, Fratta Terme , FC, IT

25/10/2015 “ Il rinforzo della trama II ed”, Fratta Terme , FC, IT

12/3/2017 “ Il rinforzo della trama IIIed”, Fratta Terme , FC, IT

15 March 2018 “Respirare e Comunicare”, Forlì, IT

8 March 2019, “Respirare e Comunicare”, AIMART, Forlì, IT

49. 11 April 2019 and 18 Nov 2019, “Diamo Respiro alle parole” Forlì, IT

5-6 Sept 2020. AMMP, Forlì (web), IT

06/2020-ongoing. Respiriamo Insieme (patient association) psychological support group for Fibrosi Polmonare Idiopatica (IPF) at Azienda Ospedaliera Universitaria Careggi Florence, IT.

Report of Scholarship

Thesis in Respiratory Medicine

27/10/2004 – Modena and Reggio Emilia University, Modena, ITALY

TITLE “A possible immunological role for dendritic cells in chronic obstructive lung disease pathogenesis: the antigen presentation process may be influenced by an impairment of their migratory ability caused by MMP12 and others MMPs/MMPs inhibitors expression imbalance”.

Principal Investigator: Prof. SD Shapiro, Respiratory and Critical Care Medicine, Harvard University, Boston, MA, USA

Chair: Prof. LM Fabbri, Respiratory Medicine, Modena and Reggio Emilia University, Modena, Italy

Peer reviewed publications in print or other media

- **Original Research investigations** (*equal contributions)

1. Orlandi M, Landini N, Sambataro G, Nardi C, Tofani L, Bruni C, Bellando-Randone S, Blagojevic J, Melchiorre D, Hughes M, Denton CP, Luppi F, Ruaro B, Della Casa F, Rossi FW, De Luca G, Campochiaro C, Spinicci M, Zammarchi L, **Tomassetti S**, Caminati A, Cavigli E, Albanesi M, Melchiorre F, Palmucci S, Vegni V, Guiducci S, Moggi-Pignone A, Allanore Y, Bartoloni A, Confalonieri M, Dagna L, De Cobelli F, De Paulis A, Harari S, Khanna D, Kuwana M, Taliani G, Lavorini F, Miele V, Morana G, Pesci A, Vancheri C, Colagrande S, Matucci-Cerinic M. THE ROLE OF CHEST CT IN DECIPHERING INTERSTITIAL LUNG INVOLVEMENT: SYSTEMIC SCLEROSIS VERSUS COVID-19. *Rheumatology (Oxford)*. 2021 Jul 28:keab615. doi: 10.1093/rheumatology/keab615. Online ahead of print.PMID: 34320649
2. Nazerian P, Sacco RM, Solbiati M, Targetti E, Marta C, Blasi F, Casazza G, Colao MG, **Tomassetti S**, Grifoni S, Rossolini GM, Costantino G Laryngotracheal aspiration test reduce the false negative rate in patients with suspected SARS-COV-2 pneumonia despite a negative nasopharyngeal swab. *Eur J Intern Med*. 2021 Jun 24:S0953-6205(21)00230-2. doi: 10.1016/j.ejim.2021.06.019. Online ahead of print.PMID: 34210553
3. Hunninghake GM, Goldin JG, Kadoch MA, Kropski JA, Rosas IO, Wells AU, Yadav R, Lazarus HM, Abtin FG, Corte TJ, de Andrade JA, Johansson KA, Kolb MR, Lynch DA, Oldham JM, Spagnolo P, Streck ME, **Tomassetti S**, Washko GR, White ES; ILA Study Group. Detection and Early Referral of Patients With Interstitial Lung Abnormalities: An Expert Survey Initiative.*Chest*. 2021 Jun 28:S0012-3692(21)01263-0. doi: 10.1016/j.chest.2021.06.035. Online ahead of print.PMID: 34197782
4. Smolinska A, Jessop DS, Pappan KL, De Saedeleer A, Kang A, Martin AL, Allsworth M, Tyson C, Bos MP, Clancy M, Morel M, Cooke T, Dymond T, Harris C, Galloway J, Bresser P, Dijkstra N, Jagesar V, Savelkoul PHM, Beuken EVH, Nix WHV, Louis R, Delvaux M, Calmes D, Ernst B, Pollini S, Peired A, Guiot J, **Tomassetti S**, Budding AE, McCaughan F, Marciniak SJ, van der Schee MP. The SARS-CoV-2 viral load in COVID-19 patients is lower on face mask filters than on nasopharyngeal swabs. *Sci Rep*. 2021 Jun 29;11(1):13476. doi: 10.1038/s41598-021-92665-3.PMID: 34188082

5. Bonifazi M, Mei F, Skrami E, Latini LL, Amico D, Balestro E, Bini F, Bonifazi F, Caminati A, Candoli P, Cinti S, Contucci S, Di Marco Berardino A, Harari S, Levi G, Lococo S, Menditto V, Marchetti G, Piciucchi S, Poletti V, Ravaglia C, Saetta M, Svegliati-Baroni G, **Tomassetti S**, Tamburrini M, Zanforlin A, Zuccon U, Zuccatosta L, Gasparini S, Carle F. Predictors of Worse Prognosis in Young and Middle-Aged Adults Hospitalized with COVID-19 Pneumonia: A Multi-Center Italian Study (COVID-UNDER50). *J Clin Med*. 2021 Mar 15;10(6):1218. 10.3390/jcm10061218.PMID: 33804084
6. Cottin V, Richeldi L, Rosas I, Otaola M, Song JW, **Tomassetti S**, Wijsenbeek M, Schmitz M, Coeck C, Stowasser S, Schlenker-Herceg R, Kolb M; INBUILD Trial Investigators. Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases. *Respir Res*. 2021 Mar 16;22(1):84. doi: 10.1186/s12931-021-01668-1.PMID: 33726766
7. Funke-Chambour M, Albera C, Bendstrup E, Costabel U, Grutters JC, Harari S, Johansson KA, Kreuter M, Strambu I, Vancheri C, Varone F, Vitulo P, Wuyts WA, Martinez F, Raghu G; **Erice participants**. Suggestions for improving clinical utility of future guidelines for diagnosis and management of idiopathic pulmonary fibrosis: results of a Delphi survey. *Eur Respir J*. 2021 Apr 29;57(4):2004219. doi: 10.1183/13993003.04219-2020. Print 2021 Apr.PMID: 33419886
8. Lentz RJ, Colt H, Chen H, Cordovilla R, Popevic S, Tahura S, Candoli P, **Tomassetti S**, Meachery GJ, Cohen BP, Harris BD, Talbot TR, Maldonado F. Assessing coronavirus disease 2019 (COVID-19) transmission to healthcare personnel: The global ACT-HCP case-control study. *Infect Control Hosp Epidemiol*. 2020 Sep 9:1-7. doi: 10.1017/ice.2020.455. Online ahead of print.PMID: 32900402.
9. Hetzel J, Wells AU, Costabel U, Colby TV, Walsh SLF, Verschakelen J, Cavazza A, **Tomassetti S**, Ravaglia C, Böckeler M, Spengler W, Kreuter M, Eberhardt R, Darwiche K, Torrego A, Pajares V, Mucic R, Musterle R, Horger M, Fend F, Warth A, Heußel CP, Piciucchi S, Dubini A, Theegarten D, Franquet T, Lerma E, Poletti V, Häntschel M. Transbronchial cryobiopsy increases diagnostic confidence in interstitial lung disease: a prospective multicenter trial. *Eur Respir J*. 2020 Aug 18:1901520. doi: 10.1183/13993003.01520-2019. Online ahead of print.PMID: 3281700.
10. **Tomassetti S**, Ravaglia C, Wells AU, Cavazza A, Colby TV, Rossi G, Ley B, Ryu JH, Puglisi S, Arcadu A, Marchi M, Sultani F, Martinello S, Donati L, Gurioli C, Gurioli C, Tantalocco P, Hetzel J, Dubini A, Piciucchi S, Klersy C, Lavorini F, Poletti V. Prognostic value of transbronchial lung cryobiopsy for the multidisciplinary diagnosis of idiopathic pulmonary fibrosis: a retrospective validation study. *Lancet Respir Med*. 2020 Aug;8(8):786-794. doi: 10.1016/S2213-2600(20)30122-3.PMID: 32763205
11. Sirol Aflah Syazatul S, Piciucchi S, **Tomassetti S**, Ravaglia C, Dubini A, Poletti V. Cryobiopsy in the diagnosis of bronchiolitis: a retrospective analysis of twenty-three consecutive patients. *Sci Rep*. 2020 Jul 2;10(1):10906. doi: 10.1038/s41598-020-67938-y.PMID: 32616807
12. Bianchi R, Dubini A, Asioli S, Ravaglia C, **Tomassetti S**, Puglisi S, Piciucchi S, Gurioli C, Gurioli C, Fiocca R, Poletti V. Transbronchial cryobiopsy: an effective tool in the diagnosis of lymphoproliferative disorders of the lung. *ERJ Open Res*. 2020 Jul 27;6(3):00260-2019. doi: 10.1183/23120541.00260-2019. eCollection 2020 Jul.PMID: 32743007
13. Occhipinti M, Bruni C, Camiciottoli G, Bartolucci M, Bellando-Randone S, Bassetto A, Cuomo G, Giuggioli D, Ciardi G, Fabbri A, **Tomassetti S**, Lavorini F, Pistolesi M, Colagrande S, Matucci-Cerinic M. Quantitative analysis of pulmonary vasculature in systemic sclerosis at spirometry-gated chest CT. *Ann Rheum Dis*. 2020 Sep;79(9):1210-1217. doi: 10.1136/annrheumdis-2020-217359. Epub 2020 Jun 30.PMID: 32606043
14. Wells AU, Flaherty KR, Brown KK, Inoue Y, Devaraj A, Richeldi L, Moua T, Crestani B, Wuyts WA, Stowasser S, Quaresima M, Goeldner RG, Schlenker-Herceg R, Kolb M;

- INBUILD trial investigators.** Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial. **Lancet Respir Med.** 2020 May;8(5):453-460. doi: 10.1016/S2213-2600(20)30036-9. Epub 2020 Mar 5.PMID: 32145830
15. Barnes H, Morisset J, Molyneaux P, Westall G, Glaspole I, Collard HR; **CHP Exposure Assessment Collaborators.** A Systematically Derived Exposure Assessment Instrument for Chronic Hypersensitivity Pneumonitis. **Chest.** 2020 Jun;157(6):1506-1512. doi: 10.1016/j.chest.2019.12.018. Epub 2020 Jan 17.PMID: 31958445
 16. Salton F, Paola Confalonieri,1,a G. Umberto Meduri,2,a Pierachille Santus,3 Sergio Harari,4 Raffaele Scala,5 Simone Lanini,6 Valentina Vertui,Tiberio Oggionni,7 Antonella Caminati,8 Vincenzo Patrino,9 Mario Tamburrini,10 Alessandro Scartabellati,11 Mara Parati,11 Massimiliano Villani,11Dejan Radovanovic,3 **Sara Tomassetti**,12 Claudia Ravaglia,13 Venerino Poletti,13 Andrea Vianello,14 Anna Talia Gaccione,15 Luca Guidelli,5 Rita Raccanelli,Paolo Lucernoni,15 Donato Lacedonia,16 Maria Pia Foschino Barbaro,16 Stefano Centanni,17 Michele Mondoni,17 Matteo Davì,17 Alberto Fantin,9Xueyuan Cao,18 Lucio Torelli,19 Antonella Zucchetto,20 Marcella Montico,20 Annalisa Casarin,21 Micaela Romagnoli,22 Stefano Gasparini,23Martina Bonifazi,23 Pierlanfranco D'Agaro,24 Alessandro Marcello,25 Danilo Licastro,26 Barbara Ruaro,1 Maria Concetta Volpe,27 Reba Umberger,18 and Marco Confalonieri. Prolonged Low-Dose Methylprednisolone in Patients With Severe COVID-19 Pneumonia. **Open Forum Infectious Diseases**, 2020. DOI: 10.1093/ofid/ofaa421
 17. Sverzellati N, Silva M, Seletti V, Galeone C, Palmucci S, Piciucchi S,Vancheri C, Poletti V, **Tomassetti S**, Karwoski R, Bartholmai BJ. Stratification of long-term outcome in stable idiopathic pulmonary fibrosis by combined longitudinal computed tomography and forced vital capacity. *Eur Radiol.* 2020 Jan 31. doi: 10.1007/s00330-019-06619-5. [Epub ahead of print] PubMed PMID: 32006172.
 18. Palmucci S, Torrisi SE, Falsaperla D, Stefano A, Torcitto AG, Russo G, Pavone M, Vancheri A, Mauro LA, Grassedonio E, Sambataro G, Puglisi S, Piciucchi S, **Tomassetti S**, Poletti V, Basile A, Vancheri C. Assessment of Lung Cancer development in Idiopathic Pulmonary Fibrosis Patients Using Quantitative High-Resolution Computed Tomography: A Retrospective Analysis. **J Thorac Imaging.** 2020 Mar;35(2):115-122. doi: 10.1097/RTI.0000000000000468. PubMed PMID: 31913257.
 19. Flaherty KR, Wells AU, Cottin V, Devaraj A, Walsh SLF, Inoue Y, Richeldi L, Kolb M, Tetzlaff K, Stowasser S, Coeck C, Clerisme-Beaty E, Rosenstock B,Quaresma M, Haeufel T, Goeldner RG, Schlenker-Herceg R, Brown KK; **INBUILD Trial Investigators.** Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. **N Engl J Med.** 2019 Oct 31;381(18):1718-1727. doi: 10.1056/NEJMoa1908681. Epub 2019 Sep 29. PubMed PMID: 31566307.
 20. Vancheri C, Sebastiani A, **Tomassetti S**, Pesci A, Rogliani P, Tavanti L, Luppi F, Harari S, Rottoli P, Ghirardini A, Kirchgassler KU, Albera C. Pirfenidone in real life: A retrospective observational multicentre study in Italian patients with idiopathic pulmonary fibrosis. **Respir Med.** 2019 Sep;156:78-84. doi:10.1016/j.rmed.2019.08.006. Epub 2019 Aug 13. PubMed PMID: 31445389.
 21. Walsh SLF, Lederer DJ, Ryerson CJ, Kolb M, Maher TM, Nusser R, Poletti V, Richeldi L, Vancheri C, Wilsher ML, Antoniou KM, Behr J, Bendstrup E, Brown KK, Corte TJ, Cottin V, Crestani B, Flaherty KR, Glaspole IN, Grutters J, Inoue Y, Kondoh Y, Kreuter M, Johannson KA, Ley B, Martinez FJ, Molina-Molina M, Morais A, Nunes H, Raghu G, Selman M, Spagnolo P, Taniguchi H, **Tomassetti S**, Valeyre D, Wijsenbeek M, Wuyts WA, Wells AU. Diagnostic Likelihood Thresholds That Define a Working Diagnosis of Idiopathic Pulmonary

- Fibrosis. **Am J Respir Crit Care Med.**2019 Nov 1;200(9):1146-1153. doi: 10.1164/rccm.201903-0493OC. PubMed PMID:31241357.
22. Lim RK, Humphreys C, Morisset J, Holland AE, Johannson KA; and the O2 **DelphiCollaborators**. Oxygen in patients with fibrotic interstitial lung disease: an international Delphi survey. **Eur Respir J.** 2019 Aug 8;54(2). pii: 1900421. doi:10.1183/13993003.00421-2019. Print 2019 Aug. PubMed PMID: 31097522.
 23. Moore C, Blumhagen RZ, Yang IV, Walts A, Powers J, Walker T, Bishop M, Russell P, Vestal B, Cardwell J, Markin CR, Mathai SK, Schwarz MI, Steele MP, Lee J, Brown KK, Loyd JE, Crapo JD, Silverman EK, Cho MH, James JA, Guthridge JM, Cogan JD, Kropski JA, Swigris JJ, Bair C, Kim DS, Ji W, Kim H, Song JW, Maier LA, Pacheco KA, Hirani N, Poon AS, Li F, Jenkins RG, Braybrooke R, Saini G, Maher TM, Molyneaux PL, Saunders P, Zhang Y, Gibson KF, Kass DJ, Rojas M, Sembrat J, Wolters PJ, Collard HR, Sundry JS, O'Riordan T, Streck ME, Noth I, Ma SF, Porteous MK, Kreider ME, Patel NB, Inoue Y, Hirose M, Arai T, Akagawa S, Eickelberg O, Fernandez IE, Behr J, Mogulkoc N, Corte TJ, Glaspole I, **Tomassetti S**, Ravaglia C, Poletti V, Crestani B, Borie R, Kannengiesser C, Parfrey H, Fiddler C, Rassl DM, Molina-Molina M, Machahua C, Worboys AM, Gudmundsson G, Isaksson HJ, Lederer DJ, Podolanczuk AJ, Montesi SB, Bendstrup E, Danchel V, Selman M, Pardo A, Henry MT, Keane MP, Doran P, Vašáková M, Sterclova M, Ryerson CJ, Wilcox PG, Okamoto T, Furusawa H, Miyazaki Y, Laurent G, Baltic S, Prele C, Moodley Y, Shea BS, Ohta K, Suzukawa M, Narumoto O, Nathan SD, Venuto DC, Woldehanna ML, Kokturk N, de Andrade JA, Luckhardt T, Kulkarni T, Bonella F, Donnelly SC, McElroy A, Armstrong ME, Aranda A, Carbone RG, Puppo F, Beckman KB, Nickerson DA, Fingerlin TE, Schwartz DA. Resequencing Study Confirms That Host Defense and Cell Senescence Gene Variants Contribute to the Risk of Idiopathic Pulmonary Fibrosis. **Am J Respir Crit Care Med.** 2019 Jul 15;200(2):199-208. doi:10.1164/rccm.201810-1891OC. PubMed PMID: 31034279; PubMed Central PMCID: PMC6635791.
 24. Ravaglia C, Bosi M, Wells AU, Gurioli C, Gurioli C, Dubini A, Piciocchi S, Puglisi S, Mascetti S, Arcadu A, **Tomassetti S**, Poletti V. Idiopathic pulmonary fibrosis: prognostic impact of histologic honeycombing in transbronchial lung cryobiopsy. **Multidiscip Respir Med.** 2019 Feb 8;14:3. doi: 10.1186/s40248-019-0170-y. eCollection 2019. PubMed PMID: 30774952; PubMed Central PMCID: PMC6367843.
 25. Bosi M, Milioli G, Parrino L, Fanfulla F, **Tomassetti S**, Melpignano A, Trippi I, Vaudano AE, Ravaglia C, Mascetti S, Poletti V. Quality of life in idiopathic pulmonary fibrosis: The impact of sleep disordered breathing. **Respir Med.** 2019 Feb;147:51-57. doi: 10.1016/j.rmed.2018.12.018. Epub 2019 Jan 10. PubMed PMID:30704699.
 26. Harari S, Caminati A, Confalonieri M, Poletti V, Vancheri C, Pesci A, Rogliani P, Luppi F, Agostini C, Rottoli P, Sanduzzi Zamparelli A, Sebastiani A, Della Porta R, Salton F, Messori B, **Tomassetti S**, Rosso R, Biffi A, Puxeddu E, Cerri S, Cinetto F, Refini RM, Bocchino M, Di Michele L, Specchia C, Albera C; ILDINET (Interstitial Lung Diseases Italian Network). The prognostic role of Gender-Age-Physiology system in idiopathic pulmonary fibrosis patients treated with pirfenidone. **Clin Respir J.** 2019 Mar;13(3):166-173. doi: 10.1111/crj.12999. PubMed PMID: 30675755.
 27. Ravaglia C, Wells AU, **Tomassetti S**, Gurioli C, Gurioli C, Dubini A, Cavazza A, Colby TV, Piciocchi S, Puglisi S, Bosi M, Poletti V. Diagnostic yield and risk/benefit analysis of trans-bronchial lung cryobiopsy in diffuse parenchymal lung diseases: a large cohort of 699 patients. **BMC Pulm Med.** 2019 Jan 16;19(1):16. doi: 10.1186/s12890-019-0780-3. PubMed PMID: 30651103; PubMed Central PMCID: PMC6335717.
 28. Cottin V, Koschel D, Günther A, Albera C, Azuma A, Sköld CM, **Tomassetti S**, Hormel P, Stauffer JL, Strombom I, Kirchgassler KU, Maher TM. Long-term safety of pirfenidone: results of the prospective, observational PASSPORT study. **ERJ Open Res.** 2018 Oct

- 19;4(4). pii: 00084-2018. doi: 10.1183/23120541.00084-2018. eCollection 2018 Oct. PubMed PMID: 30364407; PubMed Central PMCID: PMC6194203.
29. Kolb M, Raghu G, Wells AU, Behr J, Richeldi L, Schinzel B, Quaresma M, Stowasser S, Martinez FJ; **INSTAGE Investigators**. Nintedanib plus Sildenafil in Patients with Idiopathic Pulmonary Fibrosis. **N Engl J Med**. 2018 Nov 1;379(18):1722-1731. doi: 10.1056/NEJMoa1811737. Epub 2018 Sep 15. PubMed PMID: 30220235.
 30. Harari S, Caminati A, Poletti V, Confalonieri M, Gasparini S, Lacedonia D, Luppi F, Pesci A, Sebastiani A, Spagnolo P, Vancheri C, Balestro E, Bonifazi M, Cerri S, De Giacomo F, Della Porta R, Foschino Barbaro MP, Fui A, Pasquinelli P, Rosso R, **Tomassetti S**, Specchia C, Rottoli P for the ILDINET (Interstitial Lung Diseases Italian Network). A Real-Life Multicenter National Study on Nintedanib in Severe Idiopathic Pulmonary Fibrosis. **Respiration**. 2018;95(6):433-440. doi: 10.1159/000487711. Epub 2018 Mar 27. PubMed PMID: 29587263.
 31. Sverzellati N, Odone A, Silva M, Polverosi R, Florio C, Cardinale L, Cortese G, Addonizio G, Zompatori M, Dalpiaz G, Piciucchi S, Larici AR; Italian Structured Report on **Fibrosing Lung Disease Consort**. Structured reporting for fibrosing lung disease: a model shared by radiologist and pulmonologist. **Radiol Med**. 2018 Apr;123(4):245-253. doi: 10.1007/s11547-017-0835-6. Epub 2017 Dec 11. PubMed PMID: 29230680; PubMed Central PMCID: PMC5849634.
 32. Morisset J, Johannson KA, Jones KD, Wolters PJ, Collard HR, Walsh SLF, Ley B; **HP Delphi Collaborators**. Identification of Diagnostic Criteria for Chronic Hypersensitivity Pneumonitis: An International Modified Delphi Survey. **Am J Respir Crit Care Med**. 2017 Nov 27. doi: 10.1164/rccm.201710-1986OC. [Epub ahead of print] PubMed PMID: 29172641.
 33. Bosi M, Milioli G, Fanfulla F, **Tomassetti S**, Ryu JH, Parrino L, Riccardi S, Melpignano A, Vaudano AE, Ravaglia C, Tantalocco P, Rossi A, Poletti V. OSA and Prolonged Oxygen Desaturation During Sleep are Strong Predictors of Poor Outcome in IPF. **Lung**. 2017 Oct;195(5):643-651.
 34. Walsh SLF, Maher TM, Kolb M, Poletti V, Nusser R, Richeldi L, Vancheri C, Wilsher ML, Antoniou KM, Behr J, Bendstrup E, Brown K, Calandriello L, Corte TJ, Cottin V, Crestani B, Flaherty K, Glaspole I, Grutters J, Inoue Y, Kokosi M, Kondoh Y, Kouranos V, Kreuter M, Johannson K, Judge E, Ley B, Margaritopoulos G, Martinez FJ, Molina-Molina M, Morais A, Nunes H, Raghu G, Ryerson CJ, Selman M, Spagnolo P, Taniguchi H, **Tomassetti S**, Valeyre D, Wijssenbeek M, Wuyts W, Hansell D, Wells A; IPF Project Consortium. Diagnostic accuracy of a clinical diagnosis of idiopathic pulmonary fibrosis: an international case-cohort study. **Eur Respir J**. 2017 Aug 31;50(2).
 35. Ravaglia C, Wells AU, **Tomassetti S**, Dubini A, Cavazza A, Piciucchi S, Sverzellati N, Gurioli C, Gurioli C, Costabel U, Tantalocco P, Ryu JH, Chilosi M, Poletti V. Transbronchial Lung Cryobiopsy in Diffuse Parenchymal Lung Disease: Comparison between Biopsy from 1 Segment and Biopsy from 2 Segments - Diagnostic Yield and Complications. **Respiration**. 2017;93(4):285-292. doi: 10.1159/000456671. Epub 2017 Mar 1.

36. Viglietta L, Inchingolo R, Pavano C, **Tomassetti S**, Piciucchi S, Smargiassi A, Ravaglia C, Dubini A, Gurioli C, Gurioli C, Poletti V. Ultrasonography for the Diagnosis of Pneumothorax after Transbronchial Lung Cryobiopsy in Diffuse Parenchymal Lung Diseases. **Respiration**. 2017;94(2):232-236.
37. Calìo A, Lever V, Rossi A, Gilioli E, Brunelli M, Dubini A, **Tomassetti S**, Piciucchi S, Nottegar A, Rossi G, Kambouchner M, Cancellieri A, Barbareschi M, Pelosi G, Doglioni C, Cavazza A, Carella R, Graziano P, Murer B, Poletti V, Chilosi M. Increased frequency of bronchiolar histotypes in lung carcinomas associated with idiopathic pulmonary fibrosis. **Histopathology**. 2017 May 30.
38. Mariani F, Gatti B, Rocca A, Bonifazi F, Cavazza A, Fanti S, **Tomassetti S**, Piciucchi S, Poletti V, Zompatori M. Pleuroparenchymal fibroelastosis: the prevalence of secondary forms in hematopoietic stem cell and lung transplantation recipients. **Diagn Interv Radiol**. 2016 Jul 26.
39. **Tomassetti S**, Wells AU, Costabel U, Cavazza A, Colby TV, Rossi G, Sverzellati N, Carloni A, Carretta E, Buccioli M, Tantalocco P, Ravaglia C, Gurioli C, Dubini A, Piciucchi S, Ryu JH, Poletti V. Bronchoscopic Lung Cryobiopsy Increases Diagnostic Confidence in the Multidisciplinary Diagnosis of Idiopathic Pulmonary Fibrosis. **Am J Respir Crit Care Med**. 2016 Apr 1;193(7):745-52.
40. Ravaglia C, Bonifazi M, Wells AU, **Tomassetti S**, Gurioli C, Piciucchi S, Dubini A, Tantalocco P, Sanna S, Negri E, Tramacere I, Ventura VA, Cavazza A, Rossi A, Chilosi M, La Vecchia C, Gasparini S, Poletti V. Safety and Diagnostic Yield of Transbronchial Lung Cryobiopsy in Diffuse Parenchymal Lung Diseases: A Comparative Study versus Video-Assisted Thoracoscopic Lung Biopsy and a Systematic Review of the Literature. **Respiration**. 2016;91(3):215-27.
41. Harari S, Caminati A, Albera C, Vancheri C, Poletti V, Pesci A, Luppi F, Saltini C, Agostini C, Bargagli E, Sebastiani A, Sanduzzi A, Giunta V, Della Porta R, Bandelli GP, Puglisi S, **Tomassetti S**, Biffi A, Cerri S, Mari A, Cinetto F, Tirelli F, Farinelli G, Bocchino M, Specchia C, Confalonieri M. Efficacy of pirfenidone for idiopathic pulmonary fibrosis: An Italian real life study. **Respir Med**. 2015 Jul;109(7):904-13.
42. **Tomassetti S**, Gurioli C, Ryu J, Decker P, Ravaglia C, Tantalocco P, Buccioli M, Piciucchi S, Sverzellati N, Dubini A, Gavelli G, Chilosi M, Poletti V. The impact of lung cancer on survival of Idiopathic Pulmonary Fibrosis. **Chest**. 2015 Jan;147(1):157-64.
43. Ravaglia C, **Tomassetti S**, Gurioli Ch, Piciucchi S, Dubini A, Gurioli C, Casoni GL, Romagnoli M, Carloni A, Tantalocco P, Buccioli M, Poletti V. Features and outcome of familial idiopathic pulmonary fibrosis. **Sarcoidosis Vasc Diffuse Lung Dis**. 2014 Apr 18;31(1):28-36.
44. GL Casoni^{1*}, **S Tomassetti***, A Cavazza, TV Colby, A Dubini, JH Ryu, E Carretta, P Tantalocco, S Piciucchi, C Ravaglia, C Gurioli, M Romagnoli, C Gurioli, M Chilosi, V Poletti. Transbronchial Lung Cryobiopsy in The Diagnosis of Fibrotic Interstitial Lung Diseases **PLoS One**. 2014 Feb 28;9(2):e86716.
45. Chilosi M, Facchetti F, Calìo A, Zamò A, Brunelli M, Martignoni G, Rossi A, Montagna L, Piccoli P, Dubini A, Tironi A, **Tomassetti S**, Poletti V, Doglioni C. Oncogene induced senescence distinguishes indolent from aggressive forms of pulmonary and non-pulmonary Langerhans' cell histiocytosis. **Leuk Lymphoma**. 2014 Jan 29.

46. Ulivi P, Casoni GL, Foschi G, Scarpi E, **Tomassetti S**, Romagnoli M, Ravaglia C, Mengozzi M, Zoli W, Poletti V. MMP-7 and free circulating DNA serum levels in early NSCLC and idiopathic interstitial pneumonia patients. *Int J Mol Sci*. 2013 Dec 11;14(12):24097-112.
47. **S. Tomassetti**, J.H. Ryu, C. Gurioli, C. Ravaglia, M. Buccioli, P. Tantalocco, P.A. Decker, A. Cavazza, A. Dubini, V. Agnoletti, C. Gurioli, G.L. Casoni, M. Romagnoli, V. Poletti The effect of anticoagulant therapy for idiopathic pulmonary fibrosis in real life practice. *Sarcoidosis Vasc Diffuse Lung Dis*. 2013 Aug 1;30(2):121-127.
48. **Tomassetti S**, Cavazza A, Colby TV, Ryu JH, Nanni O, Scarpi E, Tantalocco P, Buccioli M, Dubini A, Piciucchi S, Ravaglia C, Gurioli C, Casoni GL, Gurioli C, Romagnoli M, Poletti V. Transbronchial biopsy is useful in predicting UIP pattern. *Respir Res*. 2012 Oct 29;13:96
49. Ley B, Ryerson CJ, Vittinghoff E, Ryu JH, **Tomassetti S**, Lee JS, Poletti V, Buccioli M, Elicker BM, Jones KD, King TE Jr, Collard HR. A multidimensional index and staging system for idiopathic pulmonary fibrosis. *Ann Intern Med*. 2012 May 15;156(10):684-91.
50. Piciucchi S, **Tomassetti S**, Casoni G, Sverzellati N, Carloni A, Dubini A, Gavelli G, Cavazza A, Chilosi M, Poletti V. High resolution CT and histological findings in idiopathic pleuroparenchymal fibroelastosis: features and differential diagnosis. *Respir Res*. 2011 Aug 23;12:111.
51. Casoni GL, Cordeiro CR Jr, **Tomassetti S**, Romagnoli M, Chilosi M, Cancellieri A, Gurioli C, Poletti V. The transbronchial lung biopsy for diagnosis of diffuse parenchymal lung disease; *Rev Port Pneumol*. 2011 Jun 28.
52. **Tomassetti S**, Carloni A, Chilosi M, Maffè A, Ungari S, Sverzellati N, Gurioli C, Casoni G, Romagnoli M, Gurioli C, Ravaglia C, Poletti V. Pulmonary features of Birt-Hogg-Dubé syndrome: cystic lesions and pulmonary histiocytoma. *Respir Med*. 2011 May;105(5):768-74. Epub 2011 Feb 26.
53. Romagnoli M, Nannini C, Piciucchi S, Girelli F, Gurioli C, Casoni G, Ravaglia C, **Tomassetti S**, Gurioli C, Gavelli G, Carloni A, Dubini A, Cantini F, Chilosi M, Poletti V. Idiopathic NSIP: an interstitial lung disease associated with autoimmune disorders? *Eur Respir J*. 2011 Jan 27.
54. Reghellin D, Poletti V, **Tomassetti S**, Dubini A, Cavazza A, Rossi G, Lestani M, Pedron S, Daniele I, Montagna L, Murer B, Chilosi M. Cathepsin-K is a sensitive immunohistochemical marker for detection of micro-granulomas in hypersensitivity pneumonitis. *Sarcoidosis Vasc Diffuse Lung Dis*. 2010 Jul;27(1):57-63.
55. Casoni GL, Ulivi P, Mercatali L, Chilosi M, **Tomassetti S**, Romagnoli M, Ravaglia C, Gurioli C, Gurioli C, Zoli W, Silvestrini R, Poletti V. Increased levels of free circulating DNA in patients with idiopathic pulmonary fibrosis. *Int J Biol Markers*. 2010 Oct-Dec;25(4):229-35.
56. Maffè A, Toschi B, Circo G, Giachino D, Giglio S, Rizzo A, Carloni A, Poletti V, **Tomassetti S**, Ginardi C, Ungari S, Genuardi M. Constitutional FLCN mutations in patients with suspected Birt-Hogg-Dubé syndrome ascertained for non-cutaneous manifestations. *Clin Genet*. 2010 Jun 7.
57. Sverzellati N, Wells AU, **Tomassetti S**, Desai SR, Copley SJ, Aziz ZA, Zompatori M, Chilosi M, Nicholson AG, Poletti V, Hansell DM. Biopsy proved idiopathic pulmonary fibrosis: spectrum of nondiagnostic thin section CT diagnoses. *Radiology*. 2010 Mar;254(3):957-64
58. G Marchesini, M Brizi, G Bianchi, **S Tomassetti**, E Bugianesi, M Lenzi, S Natale, AJ McCullough, G Forlani, N Melchionda. Non-alcoholic fatty liver disease: a feature of the metabolic syndrome. *Diabetes* 2001; 50:1844-50

- **Other peer-reviewed publications (review, case reports and case series, report of new methods, guidelines and consensus documents)**

1. Funke-Chambour M, Albera C, Bendstrup E, Costabel U, Grutters JC, Harari S, Johansson KA, Kreuter M, Strambu I, Vancheri C, Varone F, Vitulo P, Wuyts WA, Martinez F, Raghu G; Erice participants: Suggestions for improving clinical utility of future guidelines for diagnosis and management of idiopathic pulmonary fibrosis: results of a Delphi survey. *Eur Respir J*. 2021 Apr 29;57(4):2004219. doi: 10.1183/13993003.04219-2020. Print 2021 Apr. PMID: 33419886
2. Kalluri M, Luppi F, Vancheri A, Vancheri C, Balestro E, Varone F, Mogulkoc N, Cacapardo G, Bargagli E, Renzoni E, Torrisi S, Calvello M, Libra A, Pavone M, Bonella F, Cottin V, Valenzuela C, Wijsenbeek M, Bendstrup E; 3rd International Summit for ILD (ISILD), **Erice collaborators** listed below. Patient-reported outcomes and patient-reported outcome measures in interstitial lung disease: where to go from here? *Eur Respir Rev*. 2021 May 25;30(160):210026. doi: 10.1183/16000617.0026-2021. Print 2021 Jun 30. PMID: 34039675
3. Orlandi M, Landini N, Bruni C, Sambataro G, Nardi C, Bargagli E, **Tomassetti S**, Occhipinti M, Bellando Randone S, Guiducci S, Vancheri C, Colagrande S, Matucci-Cerinic M. Pleuroparenchymal fibroelastosis in rheumatic autoimmune diseases: a systematic literature review. *Rheumatology (Oxford)*. 2020 Dec 1;59(12):3645-3656. doi: 10.1093/rheumatology/keaa451. PMID: 33313932
4. George PM, Spagnolo P, Kreuter M, Altinisik G, Bonifazi M, Martinez FJ, Molyneaux PL, Renzoni EA, Richeldi L, **Tomassetti S**, Valenzuela C, Vancheri C, Varone F, Cottin V, Costabel U; Erice ILD working group. Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities. ***Lancet Respir Med***. 2020 Sep;8(9):925-934. doi: 10.1016/S2213-2600(20)30355-6. PMID: 32890499
5. Carriço F, Gurioli C, Piciocchi S, Dubini A, **Tomassetti S**, Poletti V. Pulmonary vein stenosis mimicking interstitial lung disease. ***Pulmonology***. 2020 Jun 19:S2531-0437(20)30126-4. doi: 10.1016/j.pulmoe.2020.05.010. Online ahead of print. PMID: 32571674
6. Inoue Y, Kaner RJ, Guiot J, Maher TM, **Tomassetti S**, Moiseev S, Kuwana M, Brown KK. Diagnostic and Prognostic Biomarkers for Chronic Fibrosing Interstitial Lung Diseases With a Progressive Phenotype. ***Chest***. 2020 Aug;158(2):646-659. doi: 10.1016/j.chest.2020.03.037. Epub 2020 Apr 5. PMID: 32268131
7. Cavazza A, Colby TV, Dubini A, **Tomassetti S**, Ravaglia C, Poletti V, Mengoli MC, Tagliavini E, Rossi G. Transbronchial Cryobiopsy in the Diagnosis of Diffuse Lung Disease. ***Surg Pathol Clin***. 2020 Mar;13(1):197-208. doi:10.1016/j.path.2019.11.004. Review. PubMed PMID: 32005433.
8. Poletti V, **Tomassetti S**, Gurioli C, Gurioli C, Asioli S, Piciocchi S, Dubini A, Ravaglia C, Kronborg-White S. An HIV + patient with visceral enlarged lymph nodes. ***Eur Clin Respir J***. 2019 Apr 1;6(1):1591843. doi:10.1080/20018525.2019.1591843. eCollection 2019. PubMed PMID: 30988895; PubMed Central PMCID: PMC6450598
9. Ravaglia C, Rossi G, **Tomassetti S**, Dubini A, Piciocchi S, Chilosi M, Cavazza A, Bendstrup E, Kronborg-White SB, Folkersen B, Colella S, Madsen LB, Poletti V. Report Standardization in Transbronchial Lung Cryobiopsy. ***Arch Pathol Lab Med***. 2019 Apr;143(4):416-417. doi: 10.5858/arpa.2018-0438-LE. PubMed PMID: 30920865.
10. Bargagli E, Rottoli P, Torricelli E, Allegrini C, Dubini A, Bennett D, Luzzi L, Spina D, Poletti V, **Tomassetti S**. Airway-Centered Pleuroparenchymal Fibroelastosis Associated with Non-Necrotizing Granulomas: A Rare New Entity. ***Pathobiology***. 2018;85(5-6):276-279. doi: 10.1159/000492431. Epub 2018 Sep 17. PubMed PMID: 30223268.

11. Kronborg-White S, Ravaglia C, Dubini A, Piciucchi S, **Tomassetti S**, Bendstrup E, Poletti V. Cryobiopsies are diagnostic in Pleuroparenchymal and Airway-centered Fibroelastosis. **Respir Res**. 2018 Jul 13;19(1):135. doi: 10.1186/s12931-018-0839-3. PubMed PMID: 30005615; PubMed Central PMCID: PMC6045856.
12. Hetzel J, Maldonado F, Ravaglia C, Wells AU, Colby TV, **Tomassetti S**, Ryu JH, Fruchter O, Piciucchi S, Dubini A, Cavazza A, Chilosi M, Sverzellati N, Valeyre D, Leduc D, Walsh SLF, Gasparini S, Hetzel M, Hagemeyer L, Haentschel M, Eberhardt R, Darwiche K, Yarmus LB, Torrego A, Krishna G, Shah PL, Annema JT, Herth FJF, Poletti V. Transbronchial Cryobiopsies for the Diagnosis of Diffuse Parenchymal Lung Diseases: Expert Statement from the Cryobiopsy Working Group on Safety and Utility and a Call for Standardization of the Procedure. **Respiration**. 2018;95(3):188-200. doi: 10.1159/000484055. Epub 2018 Jan 9. PubMed PMID: 29316560.
13. Poletti V, Ravaglia C, Dubini A, Piciucchi S, Rossi G, Kronborg-White S, **Tomassetti S**. How might transbronchial cryobiopsy improve diagnosis and treatment of diffuse parenchymal lung disease patients? **Expert Rev Respir Med**. 2017 Dec;11(12):913-917. doi: 10.1080/17476348.2017.1395283. Epub 2017 Oct 25. PubMed PMID: 29050527.
14. **Tomassetti S**, Ravaglia C, Poletti V. Diffuse parenchymal lung disease. **Eur Respir Rev**. 2017 Apr 26;26(144).
15. Hetzel J, Maldonado F, Ravaglia C, Wells AU, Colby TV, **Tomassetti S**, Ryu JH, Fruchter O, Piciucchi S, Dubini A, Cavazza A, Chilosi M, Sverzellati N, Valeyre D, Leduc D, Walsh SLF, Gasparini S, Hetzel M, Hagemeyer L, Haentschel M, Eberhardt R, Darwiche K, Yarmus LB, Torrego A, Krishna G, Shah PL, Annema JT, Herth FJF, Poletti V. Transbronchial Cryobiopsies for the Diagnosis of Diffuse Parenchymal Lung Diseases: Expert Statement from the Cryobiopsy Working Group on Safety and Utility and a Call for Standardization of the Procedure. **Respiration**. 2018;95(3):188-200.
16. Colella S, Clementsen PF, Gurioli C, Gurioli CH, Ravaglia C, **Tomassetti S**, Rossi A, Piciucchi S, Dubini A, Poletti V. Endobronchial-ultrasound needle aspiration and endoscopic ultrasound-fine-needle aspiration in thoracic diseases. **Pathologica**. 2016 Jun;108(2):59-79.
17. Sverzellati N, Odone A, Silva M, Polverosi R, Florio C, Cardinale L, Cortese G, Addonizio G, Zompatori M, Dalpiaz G, Piciucchi S, Larici AR; **Italian Structured Report on Fibrosing Lung Disease Consort**. Structured reporting for fibrosing lung disease: a model shared by radiologist and pulmonologist. **Radiol Med**. 2018 Apr;123(4):245-253.
18. Poletti V, Ravaglia C, Dubini A, Piciucchi S, Rossi G, Kronborg-White S, **Tomassetti S**. How might transbronchial cryobiopsy improve diagnosis and treatment of diffuse parenchymal lung disease patients? **Expert Rev Respir Med**. 2017 Dec;11(12):913-917.
19. Bosi M, Ravaglia C, **Tomassetti S**, et al. La sindrome delle apnee ostruttive nel sonno nel paziente con stroke Rassegna vol 31 p 14-18 2016
20. **Tomassetti S**. Correvva l'anno 2016. **Rassegna Mal App Resp**, 2016 in press
21. **Tomassetti S**, Ravaglia C, Poletti V. Diffuse parenchymal lung disease. **Eur Resp Rev**, 2016 in press
22. Piciucchi S, Dubini A, **Tomassetti S**, Sanna S, Ravaglia C, Carloni A, Gurioli C, Gurioli C, Colby TV, Poletti V. Angiosarcoma in the chest: radiologic-pathologic correlation: Case report. **Medicine (Baltimore)**. 2016 Nov;95(48):e5348.

23. Colby TV, **Tomassetti S**, Cavazza A, Dubini A, Poletti V. Transbronchial Cryobiopsy in Diffuse Lung Disease: Update for the Pathologist. **Arch Pathol Lab Med.** 2016 Sep 2.
24. Varone F, Mastrobattista A, Franchi P, Viglietta L, Poletti V, **Tomassetti S**, Dubini A, Tagliaboschi L, Calandriello L, Farchione A, Larici AR. Pulmonary fibrolysis in a patient with idiopathic pulmonary fibrosis: improvement of clinical and radiological pattern after treatment with pirfenidone. **Clin Respir J.** 2016 Jun 20. doi: 10.1111/crj.12515.
25. Piciucchi S, **Tomassetti S**, Ravaglia C, Gurioli C, Gurioli C, Dubini A, Carloni A, Chilosi M, Colby TV, Poletti V. From "traction bronchiectasis" to honeycombing in idiopathic pulmonary fibrosis: A spectrum of bronchiolar remodeling also in radiology? **BMC Pulm Med.** 2016 May 23;16(1):87.
26. **Tomassetti S**, Ryu JH, Piciucchi S, Chilosi M, Poletti V. Nonspecific Interstitial Pneumonia: What Is the Optimal Approach to Management? **Semin Respir Crit Care Med.** 2016 Jun;37(3):378-94.
27. Poletti V, Ravaglia C, Gurioli C, Piciucchi S, Dubini A, Cavazza A, Chilosi M, Rossi A, **Tomassetti S**. Invasive diagnostic techniques in idiopathic interstitial pneumonias. **Respirology.** 2016 Jan;21(1):44-50.
28. **Tomassetti S**, Ryu JH, Poletti V. Staging systems and disease severity assessment in interstitial lung diseases. *Curr Opin Pulm Med.* 2015 Sep;21(5):463-9.
29. Milioli G, Bosi M, Poletti V, **Tomassetti S**, Grassi A, Riccardi S, Terzano MG, Parrino L. Sleep and respiratory sleep disorders in idiopathic pulmonary fibrosis. *Sleep Med Rev.* 2016 Apr;26:57-63.
30. Poletti V, Ravaglia C, **Tomassetti S**. Transbronchial cryobiopsy in diffuse parenchymal lung diseases. *Curr Opin Pulm Med.* 2016 May;22(3):289-96.
31. **S Tomassetti**. Corveva l'anno 2015, pneumopatie infiltrative diffuse e patologia del circolo polmonare. *Rassegna di Patologia dell'Apparato Respiratorio*, 2016
32. Pietrangeli V, Piciucchi S, **Tomassetti S**, Ravaglia C, Gurioli C, Gurioli C, Cavazza A, Dubini A, Poletti V. Diffuse Neuroendocrine Hyperplasia with Obliterative Bronchiolitis and Usual Interstitial Pneumonia: An Unusual "Headcheese Pattern" with Nodules. *Lung.* 2015 Oct 7. [Epub ahead of print]
33. Antoniou KM, **Tomassetti S**, Tsitoura E, Vancheri C. Idiopathic pulmonary fibrosis and lung cancer: a clinical and pathogenesis update. *Curr Opin Pulm Med.* 2015 Nov;21(6):626-33.
34. **Tomassetti S**, Piciucchi S, Tantalocco P, Dubini A, Poletti V. The multidisciplinary approach in the diagnosis of idiopathic pulmonary fibrosis: a patient case-based review. *Eur Respir Rev.* 2015 Mar;24(135):69-77.
35. Piciucchi S, Dubini A, **Tomassetti S**, Casoni G, Ravaglia C, Poletti V. A case of amiodarone-induced acute fibrinous and organizing pneumonia mimicking mesothelioma. *Am J Respir Crit Care Med.* 2015 Jan 1;191(1):104-6.
36. **Sara Tomassetti**, Carlo Albera Domenico Aronne Marco Confalonieri Sergio Harari Maurizio Luisetti Venerino Poletti1 Luca Richeldi7 Paola Rottoli Cesare Saltini9 Carlo Vancheri1 Patrizio Vitulo. Alberto Pesci. Documento AIPO-SIMeR sulla IPF. *Rassegna di Mal App Resp*, 2015

37. **S Tomassetti.** Corveva l'anno 2014, pneumopatie infiltrative diffuse e patologia del circolo polmonare. Rassegna di Patologia dell'Apparato Respiratorio, 2015
38. Poletti V, Ravaglia C, **Tomassetti S.** Pirfenidone for the treatment of idiopathic pulmonary fibrosis. *Expert Rev Respir Med.* 2014 Oct;8(5):539-45.
39. V Poletti, GL Casoni, C Gurioli, JH Ryu, **S Tomassetti.** Lung cryobiopsies: a paradigm shift in diagnostic bronchoscopy? *Respirology.* 2014 Jul;19(5):645-54.
40. **S Tomassetti.** Corveva l'anno 2013, pneumopatie infiltrative diffuse e patologia del circolo polmonare. Rassegna di Patologia dell'Apparato Respiratorio, 2014
41. KM. Antoniou, GA. Margaritopoulos, **Sara Tomassetti**, F Bonella, U. Costabel and V. Poletti. INTERSTITIAL LUNG DISEASE: Year In Review. *Eur Respir Rev.* 2014 Mar 1;23(131):40-54.
42. V Poletti, C Ravaglia, **S Tomassetti**, C Gurioli, G Casoni, S Asioli, A Dubini, S Piciucchi, M Chilosi Lymphoproliferative lung disorders: clinicopathologic aspects. *Eur Respir Rev.* 2013 Dec;22(130):427-36.
43. **S Tomassetti^{SEP}**, JH. Ryu, G Casoni, C Gurioli, C Ravaglia, M Buccioli, P Tantalocco, C. Gurioli M Romagnoli, V Poletti. Revisione critica delle Linee Guida ATS/ERS sulla fibrosi polmonare idiopatica (IPF). Critical revision of ATS / ERS Guidelines on idiopathic pulmonary fibrosis (IPF). *Rassegna di Patologia dell'Apparato Respiratorio* 2013; 28: 74-89
44. Poletti V, Ravaglia C, Buccioli M, Tantalocco P, Piciucchi S, Dubini A, Carloni A, Chilosi M, **Tomassetti S.** Idiopathic pulmonary fibrosis: diagnosis and prognostic evaluation. *Respiration.* 2013;86(1):5-12.
45. Wells AU, Behr J, Costabel U, Cottin V, Poletti V, Richeldi L; European IPF Consensus Group. Hot of the breath: mortality as a primary end-point in IPF treatment trials: the best is the enemy of the good. *Thorax.* 2012 Nov;67(11):938-40.
46. Ravaglia C, Gurioli C, **Tomassetti S**, Casoni GL, Romagnoli M, Gurioli C, Agnoletti V, Poletti V. Is medical thoracoscopy efficient in the management of multiloculated and organized thoracic empyema?. *Respiration.* 2012;84(3):219-24.
47. J.H. Ryu, F. Maldonado and **S. Tomassetti** Idiopathic tracheopathies. *Eur Respir Mon* 2011. 54, 1–15.
48. Gurioli C, Ravaglia C, Romagnoli M, Casoni G, **Tomassetti S**, Nanni O, Poletti V EBUS-TBNA in mediastinal/hilar lymphadenopathies and/or masses: an Italian case series. *Clin Respir J.* 2012 Jan;6(1):3-8.
49. Casoni GL, Chilosi M, Romagnoli M, **Tomassetti S**, Poletti V. Another "chance" for interferon gamma 1b? *Sarcoidosis Vasc Diffuse Lung Dis.* 2011 Jul;28(1):79-80
50. Poletti V, Casoni G, Ravaglia C, Romagnoli M, **Tomassetti S.** Bronchoalveolar lavage. Technical notes. *Monaldi Arch Chest Dis.* 2011 Mar;75(1):42-3.
51. Gurioli C, Casoni GL, Gurioli C, **Tomassetti S**, Romagnoli M, Ravaglia C, Poletti V. Endobronchial ultrasound in Dieulafoy's disease of the bronchus: an additional application of EBUS. *Monaldi Arch Chest Dis.* 2010 Dec;73(4):166-8.
52. Chilosi M, **Tomassetti S**, Carloni A, Murer B. The pathologist's role in the diagnosis of idiopathic pulmonary fibrosis. *Pathologica.* 2010 Dec;102(6):443-52.
53. Ravaglia C, Gurioli C, Casoni G, Romagnoli M, **Tomassetti S**, Gurioli C, Corso RM, Poletti G, Dubini A, Marinou A, Poletti V. Diagnostic role of rapid on-site cytologic examination (ROSE) of broncho-alveolar lavage in ALI/ARDS. *Pathologica.* 2012 Apr;104(2):65-9.
54. Ryu JH, **Tomassetti S**, Maldonado F. Update on uncommon pleural effusions. *Respirology.*

2010 Nov 15.

55. Poletti V, **Tomassetti**. Ultrasound endoscopy (EBUS, EUS) as a sophisticated tool for morphological confirmation of sarcoidosis: do we need to find new answers for an old quest? *S. Sarcoidosis Vasc Diffuse Lung Dis*. 2010 Jul;27(1):5-6.
56. Chilosi M, **Tomassetti S**, Carloni A, Murer B. The pathologist's role in the diagnosis of idiopathic pulmonary fibrosis. *Pathologica*. 2010 Dec;102(6):443-52.
57. Casoni GL, **Tomassetti S**, Coffa A, Ravaglia C, Poletti V. Negative pressure pulmonary hemorrhage induced by a candy. *Am J Emerg Med*. 2010 Jan;28(1):112.
58. De Filippo, Ingegnoli A, Carloni A, Verardo E, Sverzellati N, Onniboni M, Corsi A, **Tomassetti S**, Mazzei M, Volterrani L, Poletti V, Zompatori M. Erdheim-Chester disease: clinical and radiological findings. *Diagnostic Radiology . Radiol Med*. 2009 Nov 14.
59. Romagnoli M, Bigliuzzi C, Casoni GL, Chilosi M, Carloni A, Dubini A, Gurioli Ch, **Tomassetti S**, Gurioli C, Poletti V. "The role of transbronchial lung biopsy for the diagnosis of diffuse drug-induced lung disease: a case series of 44 patients". *Sarcoidosis, Vasculitis and Diffuse Lung Diseases*, 2008.
60. Zinzani PL, Poletti V, Zompatori M, Tani M, Spaggiari L, **Tomassetti S**, Broccoli A, Derenzini E, Baccarani M. Bronchus-associated lymphoid tissue lymphomas: an update of a rare extranodal maltoma. *Clin Lymphoma Myeloma*. 2007 Nov;7(9):566-72.

- **Letters to the Editor**

1. Poletti V, **Tomassetti S**, Ravaglia C. Time to Trust Transbronchial Cryobiopsy in Identification of Usual Interstitial Pneumonia Pattern? *Am J Respir Crit Care Med*. 2021 May 15;203(10):1218-1220. doi: 10.1164/rccm.202012-4382ED. PMID: 33503399
2. Ravaglia C, **Tomassetti S**, Poletti V. New Idiopathic Pulmonary Fibrosis Guidelines: Are Cryobiopsy and Surgery Competitive in Clinical Practice? *Am J Respir Crit Care Med*. 2019 Mar 1;199(5):666-667. doi: 10.1164/rccm.201809-1718LE. PubMed PMID: 30566848.
3. Poletti V, **Tomassetti S**, Ravaglia C. Idiopathic Pulmonary Fibrosis. *N Engl J Med*. 2018 Aug 23;379(8):797. doi: 10.1056/NEJMc1807508. PubMed PMID: 30136550.
4. Ravaglia C, Gurioli C, Casoni GL, Romagnoli M, **Tomassetti S**, Gurioli C, Dubini A, Poletti V. Sarcoid-like lesion is a frequent benign cause of lymphadenopathy in neoplastic patients. *Eur Respir J*. 2013 Mar;41(3):754-5.
5. Piciocchi S, **Tomassetti S**, Colby TV, Poletti V. Role of fibrogenesis of gastroesophageal reflux and microaspiration in a patient with 12 years of radiologic follow-up. **Hum Pathol**. 2017 Jan;59:152-153.
6. G. Marchesini, M. Brizi, G. Bianchi, **S. Tomassetti**, M. Zoli, N. Melchionda. Metformin in non-alcoholic steatohepatitis. *Lancet* 2001; 358:893-4

- **Books/Textbooks for the medical or scientific community**

1. Puglisi Silvia, JH Ryu, Sara **Tomassetti** and Venerino Poletti. Multidisciplinary discussion in DPLDs. Transbronchial cryobiopsy in DPLDs. Ed Springer, 2019.
2. Puglisi Silvia, Antonella Arcadu, Claudia ravaglia, Sara **Tomassetti** and Venerino Poletti. Clinical meaning of transbronchial cryobiopsy. Transbronchial cryobiopsy in DPLDs. Ed

Springer, 2019.

3. Gurioli, S. **Tomassetti**, C. Gurioli Applicazioni dell'ecografia endobronchiale alla broncoscopia terapeutica C. In Poletti V. and Ceron L. Diagnostica ed interventistica ultrasonografica endoscopica. Edizioni minerva Medica, 2014.
4. Poletti V, Zinzani PL, **Tomassetti S**, Chilosi M. Lymphoproliferative Lung Disorders. In : Costabel U, Du Bois RM, Egan JJ (Eds). Diffuse Parenchymal Lung Disease. Progr Respir Res, Basel, Karger 2007:307-322.

- **Research publications without named authorship**

Clinton S. Robbins, Francesca Franco, Majd Mouded, Manuela Cernadas, Steven D. Shapiro (Tomassetti S cited in the Acknowledgments section). Cigarette Smoke Exposure Impairs Dendritic Cell Maturation and T Cell Proliferation in Thoracic Lymph Nodes of Mice. J Immunol. 2008 May 15; 180(10): 6623–6628.

Non-peer reviewed publications in print or other media

1. Tomassetti S1, Ravaglia C1, Gurioli C1, Chiappalone G1, Poletti V1. Prognostic assessment in IPF. Shortness of Breath, 2015
2. S. Tomassetti. Il fumo di sigaretta e la fibrosi polmonare idiopatica [Cigarettes smoke and IPF]. In: Nuovi Orizzonti. Editor: AIPO Ricerche 2008.
3. S Tomassetti. Fibrosi polmonare Idiopatica: attuali e future prospettive terapeutiche. Lung Forum, Workbook di aggiornamento in pneumologia, Sept 2014

English Language Proficiency s

IELST

BRITISH COUNCIL, Bologna, 18th January 2014

Candidate Number 11435; Passport Number AA2422927

Results: LISTENING 8.0; READING 8.5; WRITING 7; SPEAKING 7; OVERALL 7.5.

Skills in Statistics

Skills in descriptive statistics and survival analysis. Use of STATA software version 15.

Participation as a learner in the STATA one to one courses in Pavia on 9 and 26 February 2019, 6 March 2019 and 12 April 2019 (8 hours each day).

Narrative Report

My major interest embraces both clinical and research activities in the field of interventional pulmonology and rare lung diseases. My research experience started in 2003 (during my residency at Modena University, Prof. LM Fabbri) with one-year basic research fellowship with Prof. SD Shapiro at Harvard University, Boston, MA, USA focusing on the role of dendritic cells in chronic obstructive pulmonary disease. Back in Italy I started to work in clinical research with Prof. Venerino Poletti in Forlì, at the GB Morgagni Hospital, referral center for ILDs and interventional pulmonology. I have participated as principal investigator in several sponsored clinical trials for IPF treatment (National coordinator of one) and unfunded research projects (National coordinator in one). Between 2008 and 2016 I have been participating for one month every year in the Mayo Clinic Visiting Clinician Program, Rochester, MN, attending the ILD Unit with Prof. JH Ryu, the vasculitis clinic with Prof. U Specks, the bronchology unit with prof. U Prakash and the lung transplant center with prof. M. Wylam. I started my career in Italy in 2005 when I joined the staff of the Pulmonary Unit of GB Morgagni hospital, Forlì, Italy, as research fellow, in 2007 I obtained a permanent position in the staff. My clinical responsibilities in Forlì included working as consultant pulmonary physician in both inpatients and outpatients service for both general pulmonology and interventional pulmonology. I lead the former IPF Clinic at GB Morgagni Hospital in Forlì and then the ILD Clinic AIMART (ILDs, rare diseases and lung transplant) of the GB Morgagni Hospital and lately the ILD net of the Area Vasta Romagna region, IT. In November 2018 I qualified for the High Specialization title in Interstitial Lung Diseases at the USL Romagna, IT. In November 2018 I qualified for the position of Associate Professor in Respiratory Medicine, ASN, MIUR, Italy and since March 1st, 2020 I am appointed as Associate Professor of Respiratory Medicine and Head of the Interventional Pulmonology Unit at Careggi University Hospital, Florence, Italy.

My areas of expertise are interventional pulmonology (including rigid bronchoscopy both diagnostic and therapeutic and medical thoracoscopy), interstitial lung disorders and in the past lung transplant. Since 2005 I have performed more than 2000 broncoscopies (800 rigid and 350 cryobiopsy) and 76 medical thoracoscopies. I followed more than 800 patients afflicted by IPF, organized a clinical service that integrates research in real life practice and prospectively collected patients' data in one of the largest national IPF database available to date that has been used in several publications exploring the clinical profile of IPF.

Since March 2020, my major clinical responsibility is to be the Head of the Interventional Pulmonology Unit at the Careggi University Hospital in Florence, IT. I have an extensive experience in cryobiopsy implementation and standardization for the diagnosis of ILDs. We started cryobiopsy in Forlì in 2011 and until Feb 2020 we performed more than 1.300 cases in Forlì. Since March 1st 2020 I have implemented cryobiopsy in Florence (more than 150 cases in 18 months) and I'm currently investigating innovative applications and guide system such as radial EBUS and EM navigation for the diagnosis of both ILDs and lung cancer. Since I arrived in Florence I was also involved in COVID management and as interventional pulmonologist we had an active role in trials investigating the added value of BAL, including one prospective international study funded by the EU (Dragon consortium).

I have collaborated with top level international Institutions including: University of California S Francisco and Mayo Clinic, Rochester In the project entitled Staging system for IPF [Annals of Internal Medicine, 2012]; Mayo Clinic Rochester, Mayo Clinic Scottsdale, Brompton Hospital in numerous projects: Primary Pulmonary carcinoma and IPF [Chest 2014]; The role of transbronchial biopsy in UIP detection [Respiratory Research 2012]; Transbronchial cryobiopsy in the diagnosis of IPF [PLOSone, 2014 and AJRCCM, 2016 and Lancet RM, 2020]. I'm a member of the Global IPF network, Univ of Colorado, Denver, USA, investigating genetics in IPF [AJRCCM 2019] and of several other international collaboration groups.

My goal for the future is to continue to develop innovative mini-invasive diagnostic techniques and to expand my preliminary clinical experience in ILDs in referral centers, engaging in new fruitful international collaborations. My priorities are my students and my patients. Teaching to the future generations is one of the most fascinating and enriching experience I have done in this last year of professorship. Clinical research complementing clinical practice is a successful recipe that allows the medical staff to be up to date and the patients to receive the best care currently available. I really hope I'll have in the future the chance to devote more time and resources to reach this important goal.

